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Abbreviations 
AIDS Acquired immune deficiency syndrome  
CRF Circulating recombinant form 
FDA Food and Drug Administration 
FMO Fragment molecular orbital 
GB Generalized Born 
HAART  Highly active anti-retroviral therapy  
HIV Human immunodeficiency virus 
IC50 50% inhibitory concentration 
IC90 90% inhibitory concentration 
MD Molecular dynamics 
MM Molecular mechanics 
MO Molecular orbital 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NRTI Nucleoside or nucleotide reverse transcriptase inhibitor 
PB Poisson-Boltzmann 
PCA Principal component analysis 
PI Protease inhibitor 
PR Protease 
QM Quantum mechanics 
RMSD Root mean squared deviation 
RMSF Root mean squared fluctuation 
SA (Solvent accessible) surface area 
WT Wild-type 
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Human immunodeficiency virus (HIV) is one of the most hazardous viruses for humans. It is 
well known that HIV is the cause of acquired immune deficiency syndrome (AIDS). At the end of 2007, 
UNAIDS estimated that 33.2 million people were living with HIV in the world.1 Approximately 2.5 
million people were newly infected by HIV, and 2.1 million people died due to AIDS in the year. The 
majority of global HIV infections are caused by HIV type 1 (HIV-1) (Figure 1.1). The other type, HIV-2, 
is less transmittable and is largely confined to West Africa. Moreover, HIV-1 has developed an 
extraordinary degree of genetic diversity. HIV-1 has been classified into three groups labeled M (main), 
O (outlier), and N (non-M/non-O). Viruses in group M are further divided into subtypes, sub-subtypes, 
and circulating recombinant forms (CRFs).2 Subtype B virus is commonly found in patients with HIV-1 in 
developed countries such as North America, Western Europe, Australia, and, Japan.3,4 In contrast, 
developing countries suffer from epidemic of non-subtype B viruses. 
 
 
Figure 1.1. HIV-1 diversity in the worldwide epidemic.4 The frequency of each HIV-1 subtype and 
recombinant form was estimated in the respective countries based on published findings. The countries 
are colored, based on the dominant HIV-1 group M subtype. The countries colored grey have low level of 
HIV-1 prevalence or were not represented in the scientific literature related to HIV-1 subtype prevalence. 
The pie charts depict the proportion of each subtype or recombinant form in the respective geographical 
regions. The size of the pies is proportional to the number of HIV-1 infected individuals in the region. 
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Since the virus was discovered at 1983, a lot of drugs for treatment of HIV/AIDS have been 
developed5 (Table 1.1). The anti-viral drugs inhibit the functions of proteins essential for proliferation of 
of HIV (Figure 1.2). To date, the Ministry of Health, Labour and Welfare in Japan has approved three 
classes of anti-HIV drugs. The first class of the drugs is competitive inhibitors of the viral reverse 
transcriptase (nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)). The second class of the 
drugs also blocks reverse transcription of the viral RNA, but has non-competitive mechanism 
(non-nucleoside reverse transcriptase inhibitor (NNRTI)). The last class of the drugs inhibits the viral 
protease (protease inhibitor (PI)). Combination therapy of three or four of these drugs, so called highly 
active antiretroviral therapy (HAART), has resulted in remarkable decrease in morbidity and mortality 
associated with AIDS in the developed countries.6-8 HAART is quite effective in durable suppression of 
viral propagation.  
 
Table 1.1. Licensed anti-HIV drugs. 
Name Abbreviation Trade name Launched (U.S.) (Japan) 
Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) 
Zidovudine AZT (ZDV) Retovir 1987 1987 
Didanosine ddI Videx 1991 1992 
Zalcitabine ddC HIVID 1992 1996 
Stavudine d4T Zerit 1995 1997 
Lamivudine 3TC Epivir 1998 1997 
Abacavir ABC Ziagen 1999 1999 
Tenofovir TDF Viread 2001 2004 
Emtricitabine FTC Emtriva 2003 2005 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Nevirapine NVP Viramune 1996 1998 
Efavirenz EFV Sustiva, Stocrin 1998 2000 
Delavirdine DLV Rescriptor 1999 1999 
Protease inhibitors (PIs) 
Saquinavir SQV Invirase 1995 1997 
Indinavir IDV Crixivan 1996 1997 
Ritonavir RTV Norvir 1996 1997 
Nelfinavir NFV Viracept 1997 1998 
Amprenavir APV Agenerase, Prozei 1999 1999 
Lopinavir+ritonavir* LPV/r Kaletra, Aluvia 2000 2000 
Atazanavir ATV Reyataz, Zrivada 2003 2003 
Fosamprenavir FPV Lexiva, Telzir 2003 2005 
Tipranavir TPV Aptivus 2005 - 
Darunavir DRV Prezista 2006 2007 
Entry inhibitors 
Enfuvirtide T20 Fuzeon 2003 - 
Maraviroc - Celsentri, Selzentry 2007 - 
Integrase inhibitors 
Raltegravir - Isentress 2007 - 
* RTV is co-administrated to inhibit P450 and boosts blood level of LPV. 
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Figure 1.2. Life cycle of HIV.9 Text in red refers to the targets of the existing agents approved in Japan. 
Text in blue refers to the targets that are likely to be available in the near future in Japan. The 
abbreviations: RT, IN, Su, and TM in this figure, mean “reverse transcriptase”, “integrase”, “surface 
protein”, and “trans-membrane protein”, respectively. 
 
 In spite of effective HAART, the currently available drugs are unable to eradicate the virus, 
and long-term or permanent use of the drugs is required for patients infected with HIV. Therefore, 
drug-resistant variants occasionally emerge due to high mutation rate of HIV. The emergence of mutated, 
drug-resistant virus is a major cause of treatment failure.8,10-13 It has been reported that HIV genome is 
mutated a million times or much faster than mammalian DNA genome,14 due to the combined effects of 
the lack of proofreading activity of the viral reverse transcriptase, recombination between co-infected 
isolates,15,16 and high replication rate of HIV in vivo.17,18 Although high mutation rate is common 
character among retroviruses, the mutation rate of HIV is much higher than those of the other retroviruses. 
Drug-resistant HIV is a major clinical problem, not only for patients who encounter therapeutic failure 
but also for drug-naive patients. It is estimated that approximately 10% of new HIV infections harbor 
drug-resistant mutations, in North America and Europe.19-21 
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Figure 1.3. Mutations in HIV-1 protease gene associated with resistance to PIs.13 “/r” indicates 
co-administration of RTV. 
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 In addition to the problem of drug resistance, the genetic diversity of HIV makes it more 
difficult to treat HIV-infected patients. The anti-HIV drugs were developed on the basis of biophysical, 
biochemical, and in vitro studies of subtype B isolates. Fortunately, an increasing number of 
observational studies, in vitro and in vivo, suggest that the currently available inhibitors of the protease 
and the reverse transcriptase are as active against non-subtype B viruses as they are against subtype B 
viruses.22-39 However, since HIV-1 subtypes differ from one another by 10%-12% in their nucleotides and 
5%-6% in their amino acids for the protease and the reverse transcriptase,40 the various subtypes may 
respond differently to the respective antiretroviral drugs, as some in vivo and in vitro observations 
suggest.41-50 
 To date, a lot of data on genetic drug-resistant mechanisms of HIV has already been reported, 
especially about subtype B HIV-113,51-53 (Figure 1.3). Moreover, some databases54-56 provide us the 
information which mutations influence efficacy of a given anti-HIV drug and are associated with 
resistance against it. On the other hand, there are few studies on structural mechanisms of drug resistance 
due to any mutations.57-74 Hence, it is still difficult to design drugs to overcome multi-drug resistance and 
to select appropriate drugs for patients with multi-drug resistant virus. In this study, we focus on HIV-1 
protease (HIV-1 PR) and study structural mechanisms of drug resistance due to several mutations, 
through computational simulations. We also investigate role of polymorphisms in non-subtype B virus, 
from a structural viewpoint. 
 HIV-1 PR is an enzyme composed of two identical polypeptide chains, each of which consists 
of 99 amino acid residues: P1-F99 and P1’-F99’ (Figure 1.4.a). The PR has a function to process the viral 
Gag and Gag-Pol poly-protein precursors. It is interesting that the PR recognizes unique amino acid 
sequences such as Tyr-Pro or Phe-Pro, at the processing. The amide bonds of Pro residues are not 
susceptible to be cleaved by mammalian endo-peptidases. The processing is essential for the viral 
maturation, and inhibition of the function leads to an incomplete viral replication and prevents the 
infection of other cells.75 Therefore, HIV-1 PR is an attractive target for treatment of HIV/AIDS. 
Furthermore, the determination of an X-ray crystal structure of HIV-1 PR at 198976 (Figure 1.4.a) 
promotes development of HIV-1 PR inhibitors (PIs). PIs have been designed on the basis of the unique 
amino acid sequences (Figure 1.4.b). The concept of transition state mimic of substrate processing77 
(Figure 1.4.c) also improves selectivity and inhibitory activity of PIs. To date, the Ministry of Health, 
Labour and Welfare in Japan has approved nine PIs,78-84 and the Food and Drug Administration (FDA) 
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has licensed an additional PIs85,86 (Table 1.1). 
As stated above, emergence of resistant mutations against PIs is problem for treatment of 
HIV/AIDS. Among the 99 amino acid residues, mutations at about 30 positions are reported to be 
associated with resistance against PIs. According to tertiary structures of the subtype B wild-type (WT) 
HIV-1 PR with the approved PIs,89-97 some resistant mutations appear at active site of the PR in which 
amino acids directly interact with PIs (Figure 1.5). Furthermore, it is surprising that mutations at 
non-active site of HIV-1 PR, in which residues do not have any direct interaction with PIs, are also 
associated with resistance against PIs. Active site mutations may reduce direct interactions with PIs to 
confer resistance against PIs. In contrast, it is difficult to speculate how non-active site mutations are 
associated with resistance against PIs. 
In this study, we perform computational simulations to clarify structural roles of resistant 
mutations and polymorphisms in HIV-1 PR. We apply the molecular dynamics (MD) method to predict 
 
Figure 1.4. (a) Tertiary structure and the sequence of subtype B wild-type (WT) HIV-1PR. The PR has 
two identical polypeptide chains, each of which consists of 99 residues: P1-F99 and P1’-F99’. The 
catalytic aspartates D25/D25’ are shown in ball and stick representations. The numbers indicate the 
locations of amino acids. The structure of HIV-1 PR is drawn by the PyMOL ver. 0.99.rc6.87 (b) 
Chemical structures of Phe-Pro and PIs: saquinavir (SQV)78 and nelfinavir (NFV).82 (c) Mechanism of 
cleavage of Phe-Pro catalyzed by D25/D25’ in HIV-1 PR.88 
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structure of complex of HIV-1 PR and its ligand in solution, and the MM_PBSA/GBSA approach to 
estimate binding affinity of the complex (See the Appendix). First, we examine resistant mechanisms not 
only due to active site mutation D30N in HIV-1 PR, and also due to non-active site mutations L90M and 
N88S. It is well know that all of three mutations confer resistance against nelfinavir (NFV), which is one 
of the FDA-approved PIs. A substitution of asparagine (N) for aspartic acid (D) at codon 30 (D30N) 
occurs in subtype B HIV-1 PR and confers specific resistance against NFV.13,98,99 A substitution of 
methionine (M) for leucine (L) at codon 90 (L90M) occasionally appears in patients for whom treatment 
with NFV has failed.13,51-53,98,99 Moreover, L90M is known to be associated with most of the approved 
PIs.13,51-53,100-103 A substitution of serine (S) for aspargine (N) at codon 88 (N88S) is commonly seen in 
patients with CRF01_AE HIV-1 for whom treatment with NFV has failed. 46,104,105 Second, we attempt to 
clarify role of polymorphisms in non-subtype B HIV-1 PR. We investigate how polymorphisms in 
CRF01_AE HIV-1 PR are associated with emergence of mutations D30N and N88S. It have been 
reported that D30N is more frequently observed in patients with subtype B HIV-1 than N88S.46 
Oppositely, N88S occasionally appears in patients with CRF01_AE HIV-1 and D30N does not emerges 
in them. We also examine structural role of non-active site mutation M36I in HIV-1 PR, which is the 
most frequently observed polymorphism in non-subtype B HIV-1.50 
The computational simulations provide the atomistic level of understanding of the roles of 
resistant mutations or polymorphisms in HIV-1 PR. Our findings will be useful to design better inhibitors 
that maintain efficacy even for multi-drug-resistant virus. Moreover, the simulation will be also 
applicable to select an appropriate regimen for each patient with HIV-1. 
 
Figure 1.5. Structure of HIV-1 PR showing (a) the distribution of mutations in untreated patients; (b) the 
difference in occurrence probability of mutations between untreated and treated patients.106 Mutations 
with a total probability higher than 5% are indicated in the figure. 
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Chapter 2 
Resistant Mechanism against NFV 
 due to D30N in HIV-1 PR 
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Introduction 
 In this chapter, we examine how a substitution of aspargin (N) for aspartate (D) at codon 30 
(D30N) in HIV-1 protease (HIV-1 PR) confers resistance against nelfinavir (NFV) (Figure 2.1.a). D30N 
often appears in patients infected with subtype B HIV-1 for whom treatment with NFV has failed.13,82,98 
The emergence of D30N in subtype B virus confers specific resistance against NFV. Furthermore, the 
combination of D30N and N88D is the most commonly seen in the patients. It appears that N88D 
compensates for the loss of replication capacity resulting from D30N as a secondary mutation.82,98 
 According to an X-ray crystal structure of HIV-1 PR in complex with NFV,94 D30 is located 
at active site of the PR and has hydrogen bond with the m-phenol group of NFV (Figure 2.1.b). Hence, 
D30N mutation will alter the direct electrostatic interaction with NFV at the active site. Recently, 
Mahalingam and co-workers determined some high-resolution X-ray crystal structures of D30N mutants 
in complex with peptide inhibitor analogues, not NFV.58,60,62 They found that D30N altered the interaction 
with the inhibitors. Although D30N mutation was suggested to influence the interaction inside the active 
site, a clear explanation on the resistant mechanism against NFV due to D30N has not been provided yet. 
To clarify the mechanism due to D30N, we investigate the subtype B wild-type (WT) HIV-1 
PR and D30N, N88D, and D30N/N88D mutants in complex with NFV, through computational approach. 
 
 
Figure 2.1. (a) Chemical structure of NFV. (b) X-ray structure of complex of HIV-1 PR and NFV. 94 The 
PR has two identical polypeptide chains, each of which consists of 99 residues: P1-F99 and P1’-F99’. 
The two catalytic aspartates D25/D25’, D30 and N88 in the PR and NFV are shown in stick 
representation. The structure is drawn by the PyMOL ver. 0.99.rc6.87 (c) The sequence of the subtype B 
wild-type (WT) HIV-1 PR. 
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Materials and Methods 
Molecular Dynamics (MD) Simulation. All the minimizations and MD simulations in this chapter are 
performed with the sander module of the AMBER 7 package.107,108 The AMBER ff99 force field109 is used 
in the simulations. Since there is no information about the atom charges for NFV in the package, we 
determine the atom charges by the following methods and apply the charges to the simulations. First, 
quantum mechanical (QM) calculation at the B3LYP/6-31G(d,p) level is carried out to optimize 
conformation of NFV using the Gaussian 98 program.110 Second, the electrostatic potential of NFV is 
calculated at the same level. Last, the partial atom charges for NFV are determined using the RESP 
method,111 so that the atom charges can reproduce the values of the calculated electrostatic potential at the 
surrounding points of NFV. Charges are set equal between two atoms if they are the same element and 
have the same bond coordination. Each initial structure for the wild-type (WT) PR of subtype B HIV-1 
and D30N, N88D, and D30N/N88D mutants in complex with NFV (labeled PR(B:WT)NFV, 
PR(B:D30N)NFV, PR(B:N88D)NFV, and PR(B:D30N/N88D)NFV) is modeled on the basis of the coordinates 
of an X-ray crystal structure (PDB code: 1OHR)94 using the LEaP module. All the crystal water 
molecules are included in each model. Each model is placed in a rectangular box filled with about 8000 
TIP3P water molecules.112 The expansion and shrinkage of all covalent bonds connecting to hydrogen 
atoms are constrained using the SHAKE algorithm.113 The periodic boundary condition114-116 is applied to 
avoid edge effects in all calculations. When using the periodic boundary condition, particles are enclosed 
in a box, and we can imagine that the box is replicated to infinity by translation in all the three cartesian 
directions, completely filling the space. The particle mesh Ewald method114-116 is applied to compute the 
long-range interaction energy under the periodic boundary condition. The cutoff distance for the 
long-range electrostatic and the van der Waals terms is 12.0 Å. Energy minimization is achieved via three 
stages. At first, movement is allowed only for water molecules and ions. Next, ligand and mutated 
residues are allowed to move in addition to the water molecules and ions. Last, all atoms are permitted to 
move freely. In each stage, the energy minimization is executed by the steepest decent method for the 
first 1000 steps and the conjugated gradient method for the subsequent 3000 steps. The protonation states 
of the catalytic aspartates D25 and D25’ vary depending on sequence of HIV-1 PR or the binding 
ligand.117 Therefore, the protonation states of the catalytic aspartates are determined, by performing 
energy minimizations for all combinations of protonation states (D25/D25’ both protonated, D25/D25’ 
both un-protonated, D25 protonated and D25’ un-protonated, D25 un-protonated and D25’ protonated). 
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Since the combination with protonated D25 and un-protonated D25’ shows the lowest total potential 
energy, we adopted this combination in the simulations. After 24-ps heating calculations until 300 K 
using the NVT ensemble (constant number of atoms, constant volume and constant temperature), MD 
simulations are executed using the NPT ensemble (constant number of atoms, constant pressure and 
constant temperature) at 1 atm and at 300 K for 1 ns, with an integration time step of 1.0 fs. After 500-ps 
equilibrating calculations, the MD simulations showed no large fluctuations (Figure 2.2). The coordinates 
of 200 snapshots at the intervals of 0.5 ps are obtained as structural data; those are collected for the last 
100 ps of the simulations. 
 
 
Figure 2.2. Root mean squared deviation (RMSD) (Å) of main chain atoms: N, C?, C in each model 
compared with those in the X-ray crystal structure.94 The last 100 ps are highlighted with a yellow 
background. 
 
Hydrogen Bond Criteria. The formation of a hydrogen bond is defined in terms of distance and 
orientation. The combination of donor D, hydrogen H, and acceptor A atoms with a D-H…A 
configuration is regarded as a hydrogen bond when the distance between donor D and acceptor A is 
shorter than Rmax and the angle H-D-A is smaller than ?max. The values of 3.5 Å and 60.0 degree are 
adopted for Rmax and ?max. 
Buried Surface Area. The magnitude of the buried surface area66 is related to the strength of the 
hydrophobic interaction between a receptor and a ligand. The buried surface area is defined as 
solvent-accessible surface areas118 buried by binding of ligand to receptor. A surface area is computed for 
the complex of a receptor and a ligand (SAcom). A surface area is also calculated only for the ligand (SAlig) 
and only for the receptor (SArec). We obtain the buried surface area from the difference between the 
unbound and the ligand-bound cases (SAlig + SArec - SAcom). The solvent-accessible surface areas are 
computed with the Paul Beroza’s molsurf program, which is based on the analytical technique primarily 
developed by Connolly.119 
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Binding Energy Calculation. The binding free energy120 is calculated with the MM_PBSA method on 
the basis of the next equation: 
?G b = ?G MM +?G sol ?T?S 
 , 
where ?Gb  is the binding free energy in solution, ?GMM  is the interaction energy between a ligand 
and a protein, ?G sol  is the solvation energy, and -T?S is conformational entropy contribution to the 
binding. When it is assumed that the entropies are almost the same in magnitude among the mutants, the 
difference in entropy is disregarded in the comparison of the binding energy. ?GMM  is calculated from 
molecular mechanics (MM) interaction energy: 
?GMM = ?G int
ele
+?G int
vdW , 
where ?G int
ele  and ?G int
vdW  are the electrostatic and van der Waals interaction energies between the 
ligand and the protein. These energies are computed using the same parameter set with the simulation, 
and no cutoff is applied for the calculation. The solvation energy ?G sol  can be divided into to the two 
parts: 
?G sol = ?G sol
ele
+?G sol
nonpol . 
The electrostatic contribution to the solvation free energy ( ?G sol
ele ) is calculated with the 
Poisson-Boltzmann (PB) method using the DelPhi program.121 The interior dielectric constant is set to 1.0, 
and the exterior dielectric constant to 80.0. The hydrophobic contribution to the solvation free energy 
( ?G sol
nonpol ) is determined as a function of the solvent-accessible surface area (SA).122 
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Results 
Change in Conformation of Mutant PR. To study the drug-resistant mechanism due to D30N, we first 
compared the averaged atom coordinates of PR(B:WT)NFV with those of each mutant. The least-squared 
rigid body superposition indicates that no large conformational alteration appears in the shape of HIV-1 
PR for every mutant (Figure 2.3). The RMSD values compared with PR(B:WT)NFV is 0.8 Å in 
PR(B:D30N)NFV, 0.9 Å in PR(B:N88D)NFV, and 0.6 Å in PR(B:D30N/N88D)NFV, when calculated by using 
the coordinates of main chain atoms N, C?, and C. The detailed analysis of individual residues and the 
comparison of the local structures, however, provided new understanding on the conformational changes 
due to the respective mutations. Although large deviations are seen at the residues of the outside loop 
region, those residues are not minutely examined because their large fluctuations are commonly observed 
in B-factor analysis (Figure 2.4). In PR(B:N88D)NFV, peculiar conformational changes occur at the ? 
sheets consisting of Y59-V75 (RMSD: 1.4 Å) and Y59’-V75’ (RMSD: 1.2 Å). Those regions move far 
away from the helix region (R87-L90/R87’-L90’). PR(B:D30N/N88D)NFV exhibits the similar 
conformational changes at the same but much narrower regions of those ? sheets: T74/T74’ and its 
vicinity. On the other hand, PR(B:D30N) hardly shows large change in conformation except at the 
outside loop regions. 
 
Figure 2.3. 3D plots of RMSD between the average structures of PR(B:WT)NFV and each mutant, traced 
over every main chain atom. Each mutant structure is superimposed on PR(B:WT)NFV, which is 
represented by white tubes. In each PR, the left chain consists of P1-F99, and the right one consists of 
P1’-F99’. The color represents the magnitude of RMSD shown at the right bar. Each structure is drawn 
by the PyMOL ver. 0.99.rc6.87 
 
Figure 2.4. B-factor values for the main chain atoms in PR(B:WT)NFV and mutated PRs. In each PR, the 
left chain consists of P1-F99, and the right one consists of P1’-F99’. The color represents the magnitude 
of B-factor shown at the right bar. Each structure is drawn by PyMOL ver. 0.99.rc6.87 
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Hydrogen bonds between PR and NFV. In interactions between a protein and a ligand, hydrogen bonds 
play an important role in stabilizing the complex. Hydrogen bonds between each PR and NFV in every 
model are listed in Table 2.1. Analysis of the hydrogen bonds suggests that mutation has obviously 
influenced the hydrogen bond network between HIV-1 PR and NFV. Only a few residues are responsible 
for the hydrogen bonds with NFV. Hydrogen bond networks consist of D25/D25’ (catalytic aspartates), 
I50/I50’, D30, some water molecules, and NFV. The direct interaction between the carboxyl group of the 
un-protonated aspartate D25’ and the central hydroxyl group of NFV is frequently seen in every model, 
whereas the protonated aspartate D25 hardly interacts with NFV. In PR(B:WT)NFV, D30 directly interacts 
with the m-phenol group of NFV. In PR(B:N88D)NFV, a water molecule mediates a hydrogen bond 
between D30 and NFV, although the distance between the m-phenol group of NFV and D30 is elongated. 
On the other hand, no hydrogen bond is observed between N30 and NFV in PR(B:D30N)NFV and 
PR(B:D30N/N88D)NFV. D30N mutation causes the disappearance of the hydrogen bond network between 
the 30th residue of HIV-1 PR and NFV, because those mutants increase the distances between the 
m-phenol group of NFV and the 30th residue and cannot keep any water molecule (Figure 2.5.a). A water 
molecule exists between I50/I50’ and NFV in all models. This water molecule mediates the 
intra-molecular and inter-molecular hydrogen bonds, which results in stabilizing complex of each PR and 
NFV. In PR(B:WT)NFV, the water molecule links the main chain of I50’ with NFV. Further, a direct 
hydrogen bond between the sulfur atom of NFV and the main chain of I50 is detected and no water 
molecule mediates the hydrogen bond from I50. In contrast, the water molecule mediates the hydrogen 
bond between NFV and both I50 and I50’ in PR(B:D30N)NFV. NFV forms a hydrogen bond network with 
I50’ in the other two models (PR(B:N88D)NFV and PR(B:D30N/N88D)NFV). Both NFV and the water 
molecule hardly interact with the main chain of I50. Interestingly, a water molecule mediating a hydrogen 
bond with D29’ is frequently observed in the simulations of PR(B:D30N)NFV (occupancy is 85.0%). 
Another water molecule mediating an intra-molecular hydrogen bond in NFV is located near the catalytic 
aspartates in both PR(B:WT)NFV and PR(B:D30N)NFV.  
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Table 2.1. Hydrogen bond network in each model. 
(a) D25/D25’ 
Donor Acceptor %* Donor Acceptor % 
WT D30N 
O3 NFV OD1 D25’ 91.0 O3 NFV OD2 D25’ 100.0 
O3 NFV OD2 D25’ 95.5      
O WAT208 O3 NFV 60.0 N1 NFV O WAT210 85.0 
O WAT208 OD2 D25’ 61.0 O WAT210 O3 NFV 52.5 
N1 NFV O WAT208 59.5      
N88D D30N/N88D 
O3 NFV OD2 D25’ 100.0 O3 NFV OD2 D25’ 96.5 
(b) I50/I50’ 
Donor Acceptor % Donor Acceptor % 
WT D30N 
N I50 S1 NFV 61.0 O WAT207 O4 NFV 76.5 
O WAT205 O4 NFV 51.5 O WAT207 O2 NFV 89.0 
N I50’ O WAT205 61.0 N I50 O WAT207 50.5 
     N I50’ O WAT207 93.5 
N88D D30N/N88D 
O WAT203 O4 NFV 79.5 O WAT205 O4 NFV 98.5 
O WAT203 O2 NFV 95.0 O WAT205 O2 NFV 97.5 
N I50’ O WAT203 100.0 N I50’ O WAT205 96.5 
(c) D30 
Donor Acceptor % Donor Acceptor % 
WT D30N 
O1 NFV O D30 90.0      
N D30 O1 NFV 64.5      
N88D D30N/N88D 
O WAT3880 O1 NFV 59.0      
N D30 O WAT3880 87.5      
O WAT3880 O D30 97.5      
The listed donor and acceptor pairs satisfy the criteria for the hydrogen bond over 50.0% of time during 
the last 100 ps simulation. Nomenclature of atoms is shown in Figure 2.1.a. 
* Occupancy of hydrogen bonds. 
 
 
Figure 2.5. (a) Hydrogen bonds between the 30th residue and NFV in PR(B:WT)NFV and PR(B:D30N)NFV. 
(b) Hydrogen bond network surrounding the 88th residue of PR(B:WT)NFV and PR(B:N88D)NFV. Orange 
dotted lines show hydrogen bonds. Each structure is drawn by the PyMOL ver. 0.99.rc6.87 
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In addition to the interactions at the active site, N88D mutation modulates the hydrogen bond 
network at the surroundings of the 88th residues (Figure 2.5.b). In PR(B:WT)NFV, the main chain of N88 
has a direct hydrogen bond with the main chain of D29, and the side chain of N88 interacts with the side 
chain of T31. Those hydrogen bonds are also observed in the opposite subunit. Further, one water 
molecule links N88 with T74 (occupancy is 93.5%) and N88’ with T74’ (75.5%). In PR(B:D30N)NFV, the 
88th residues in both subunits also have the same hydrogen bond networks as the 29th, 31st, and 74th 
residues. But, in PR(B:N88D)NFV and PR(B:D30N/N88D)NFV, the water-molecule-mediated hydrogen 
bonds are not observed. That is, N88D mutation induces the disappearance of the 
water-molecule-mediated- hydrogen bonds, though the direct hydrogen bonds are retained. 
Hydrophobic Interactions between PR and NFV. Hydrophobic interactions and van der Waals 
interactions also contribute to stabilizing the complex. We calculated surface area buried by binding of 
PR with NFV, to evaluate the magnitude of hydrophobic interaction between HIV-1 PR and NFV. The 
results in Table 2.2 and Figure 2.6 show that most of the buried residues are hydrophobic ones. The 
stabilization of NFV by hydrophobic interaction is mainly due to I50/I50’ and I84/I84’, and secondly 
A28/A28’, G48/G48’, and P81’. D30N mutation hardly affects the buried surface area, whereas N88D 
mutation increases the buried surface area. 
 
Table 2.2. Buried surface area and the contribution of hydrophobic and hydrophilic residues. 
 WT D30N N88D D30N/N88D 
Buried surface area (Å2) 805.9 809.9 841.5 832.6 
Hydrophobic : Hydrophilic* 83.0 : 17.0 82.8 : 17.2 83.1 : 16.9 86.1 : 13.9 
* Hydrophobic residue:  Gly / Ala / Val / Leu / Ile / Met / Pro / Phe / Trp 
 Hydrophilic residue:  Ser / Thr / Asn / Gln / Tyr / Cys / Lys / Arg / His / Asp / Glu  
 
 
Figure 2.6. Buried surface areas due to each involved residue. The left graph represents those in one 
chain, and the right graph represents those in the other chain. 
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Binding Energy Calculation. Table 2.3 shows the binding energy between HIV-1 PR and NFV. Each 
mutation causes a distinctive energetic change from PR(B:WT)NFV. PR(B:D30N)NFV decreases the 
electrostatic energy greatly. PR(B:N88D)NFV becomes more stable because of the electrostatic 
contribution by the solvation effect than PR(B:WT)NFV. PR(B:D30N/N88D)NFV has both characters of 
PR(B:D30N)NFV and PR(B:N88D)NFV. PR(B:D30N/N88D)NFV is less stable than PR(B:N88D)NFV because 
of the loss of the electrostatic interactions. In contrast, PR(B:D30N/N88D)NFV has more favorable 
solvation effect than PR(B:D30N)NFV. Consequently, PR(B:D30N/N88D)NFV shows the loss of the binding 
energy similar to PR(B:D30N)NFV. These energetic results are compatible with the indices of the 
resistance level that were estimated from experimentally determined 90% inhibitory concentration 
(IC90).
82,98 
 
Table 2.3. Binding free energies of the WT model and mutants. 
 ?G int
ele  
(kcal/mol) 
?G int
vdW  
(kcal/mol) 
?G sol
nonpol  
(kcal/mol) 
?G sol
ele  
(kcal/mol) 
?G int+sol
ele  
(kcal/mol) 
?G b
 † 
(kcal/mol) 
Resistance 
level* 
WT -26.5±4.2 -66.4±3.3 -4.5±0.1 44.2±3.4 17.7±3.5 -53.2±4.2 - 
D30N -19.2±2.8 -64.0±2.8 -4.5±0.2 38.2±3.6 19.0±3.7 -49.5±3.5 6 
N88D -26.2±3.5 -66.0±3.5 -4.7±0.3 42.6±3.7 16.4±3.6 -54.3±3.9 0.6 
D30N/N88D -15.1±3.9 -64.9±3.3 -4.6±0.2 35.4±3.7 20.3±3.8 -49.2±4.0 6 
* The data is referred from the references 82, 98. 
† -T?S 
 is not included. 
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Discussion 
We performed MD simulations of PR (B:WT)NFV, PR(B:D30N)NFV, PR(B:N88D)NFV, and 
PR(B:D30N/N88D)NFV to understand the resistant mechanism against NFV due to active site mutation 
D30N. D30N is a primary mutation of NFV, which specifically emerges during treatment of subtype B 
HIV-1 with NFV.82,98 Moreover, D30N often appears with the secondary mutation N88D. It appears that 
N88D compensates for the loss of replication capacity resulting from D30N. 82,98 The X-ray crystal 
structure of PR(B:WT)NFV shows that the m-phenol group of NFV interacts with D30 of HIV-1 PR.
94 
Hence, D30N mutation has been assumed to make less hydrophilic contacts with NFV and confers 
resistance against NFV. 
The recent docking study by Clemente et al. indicates that PR(B:D30N)NFV would maintain 
the hydrogen bond between N30 and NFV but weakens the strength of the hydrogen bonding due to 
decrease of acid-base interaction.65 However, their computational model could move only NFV and the 
side chain of N30 in the vacuum condition without any water molecules. That is, their docking 
simulations did not consider the contributions of the movement of the residues other than N30 nor 
solvation effects. MD simulation is useful to incorporate these contributions and to provide more detailed 
information. The direct hydrogen bonds are observed between the m-phenol group of NFV and D30 in 
PR(B:WT)NFV. On the other hand, PR(B:D30N)NFV and PR(B:D30N/N88D)NFV show no hydrogen bonds 
between them. D30N cancels those hydrogen bonds and greatly decreases the electrostatic interaction 
energy. 
The simulations also explain influence of N88D on binding with NFV. We have detected that 
N88D induces the increase of hydrophobic contacts between PR and NFV, although the 88th residue is 
not located at active site of HIV-1 PR. The increase of the hydrophobic contacts might induce the 
compensation for the loss of replication capacity resulting from D30N and keep the binding affinity with 
substrates of HIV-1 PR. On the other hand, N88D mutation enhances the loss of electrostatic interaction 
with NFV due to D30N. Therefore, D30N/N88D do not change the resistant level against NFV, compared 
with D30N. 
 The simulations provide important structural information to understand the resistant 
mechanism. We expect that the information will help to design much potent inhibitors. 
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Chapter 3 
Multi-drug Resistant Mechanism 
 due to L90M in HIV-1 PR 
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Introduction 
Non-active site mutation L90M in HIV-1 protease (HIV-1 PR) is a primary mutation 
responsible for resistance against not only nelfinavir (NFV) but also saquinavir (SQV).82,98,100,101 L90M 
also appears to be associated with resistance to the other FDA-approved PIs. 13,52,53 Although the 90th 
residue of the PR cannot directly interact with the PIs (Figure 3.1.a), L90M is associated with high level 
of resistance against the PIs.13,51-53,82,98,100,103 However, it is difficult to understand how L90M leads to the 
resistance. The structures of L90M PR in complex with PIs have been determined through X-ray 
crystallographic approaches by some groups.59,62 These structures showed that the side chains of the 
mutated M90/M90’ altered their interactions with the catalytic aspartates D25/D25’. Nevertheless, the 
mechanism of resistance due to L90M still remains to be clarified. 
In this chapter, we carried out molecular dynamics (MD) simulations and binding energy 
calculations of L90M PR in complex with several kinds of ligands to clarify the mechanism of resistance 
due to L90M. NFV, SQV, and lopinavir (LPV) are selected as representative PIs currently used in the 
clinical field (Figure 3.1.b). NFV and SQV reduce their ability to inhibit the function of HIV-1 PR that has 
acquired L90M mutation. In contrast, single mutations have little effect on the inhibition ability of LPV.123 
In addition, the oligo-peptide at the PR/RT cleavage site (PRRT) was selected as a typical substrate for the 
enzyme to investigate the effect of L90M on substrate binding (Figure 3.1.b). The PR/RT cleavage site 
contains Phe-Pro at the P1-P1’ residues (notation by Schecter and Berger,124 Figure 3.1.c). It is unusual for 
mammalian endo-peptidases to cleave the peptide bond located at the N-terminal side of Pro, and this 
cleavage site is specific to HIV-1 PR.125,126 This cleavage mechanism is unique as reported previously.88 
Therefore, the structure of PRRT was used as the base of drug design for NFV, SQV, and some PIs.77,78,82 
First, the binding energies of NFV, SQV, LPV, and PRRT were calculated to compare the affinities of the 
wild type (WT) PR and L90M mutant. The binding structures were then compared in two groups of 
inhibitors: one groups consisting of inhibitors that reduce drug efficacy due to L90M mutations, such as 
NFV and SQV, and the other group consisting of drugs that maintain efficacy, such as LPV. The results 
indicate that L90M influences active site residues to confer resistance against PIs, although the 90th residue 
is located at non-active site of HIV-1 PR. 
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Figure 3.1. (a) X-ray crystal structure of HIV-1 PR.94 The PR has two identical polypeptide chains, each 
of which consists of 99 residues P1-F99 and P1’-F99’. Locations of the two catalytic aspartates D25/D25’, 
the 84th and the 90th residues, are shown in stick representation. The structure is drawn by the PyMOL 
ver. 0.99.rc6.87 The wild-type (WT) sequence of subtype B HIV-1 PR is shown below. (b) Chemical 
structures of NFV, SQV, LPV, and PRRT. Each red dotted line shows a junction between sites. The P1 
site is highlighted with an orange background, and the P1’ site is highlighted with a yellow background. 
(c) Definition of P4-P4’ sites by Schecter and Berger.124 
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Materials and Methods 
Molecular Dynamics (MD) Simulation. We perform energy minimizations and MD simulations as in a 
manner similar to that described in the chapter 2. Before carrying out MD simulations, quantum 
mechanical (QM) calculations are executed for PIs to deduce the atom charges utilized in MD simulations. 
Geometry optimization is performed on each PI, and the electrostatic potential is calculated at the 
B3LYP/6-31G(d,p) level using the Gaussian 03 program.127 The partial atom charges are determined 
using the RESP method111 so that the atom charges can reproduce the values of the calculated electrostatic 
potential at the surrounding points of the PI. Charges are set equal between two atoms if they are the same 
element and had the same bond coordination. Minimizations and MD simulations are carried out using 
the sander module of the AMBER 7 package.107,108 The AMBER ff02 force field109 is used as the 
parameters for the van der Waals and bonded energy terms basically, and the general AMBER force 
field128 is used as the parameters for NFV, SQV, and LPV. Each initial structure for subtype B PR in 
complex with NFV, SQV, and LPV is modeled from the atom coordinates of an X-ray crystal structure 
(PDB code: 1OHR,94 1HXB,77,89 and 1MUI,95 respectively) using the LEaP module (Figure 3.1.a). The 
initial structure for PR in complex with PRRT before the catalytic reaction is modeled in the same 
manner as that previously reported.88 The oligo-peptide of ACE-Thr-Leu-Asn-Phe-Pro-Ile-Ser-NME is 
utilized as PRRT (Figure 3.1.b), and one water molecule is inserted between PRRT and D25/D25’. Each 
model is placed in a rectangular box filled with about 8000 TIP3P water molecules,112 with all of the 
crystal water molecules remaining. One water molecule is added between LPV and I50/I50’ in the LPV 
complex model, because no crystal water molecule is present in the crystallographic data. It is known that 
the hydrogen bonds between PI and I50/I50’ via the water molecule are critically important for PI binding 
with HIV-1 PR.88,129,130 After 52.0 ps heating calculation until 300 K using the NVT ensemble, 1.5 ns 
equilibrating calculation is executed at 1 atm and at 300 K using the NPT ensemble, with an integration 
time step of 1.0 fs. In the present calculations, the MD simulations show no large fluctuations after about 
500 ps equilibrating calculation (Figure 3.2 and Table 3.1). Hence, atom coordinates are collected at the 
interval of 0.5 ps for the last 500 ps to analyze the structure in detail. In this chapter, WT PR with each of 
NFV, SQV, LPV, and PRRT are labeled as PR(B:WT)NFV,
 
 PR(B:WT)SQV,
 PR(B:WT)LPV, and
 
PR(B:WT)PRRT. L90M PR with each ligand is labeled as PR(B:L90M)NFV,
 
 PR(B:L90M)SQV,
 
PR(B:L90M)LPV, and
 PR(B:L90M)PRRT. 
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Figure 3.2. RMSD plot during each MD simulation. RMSD were calculated from the coordinates of main 
chain atoms N, C?, C and the residues at codon 8, 23-32, 47-50, 81-84 are selected as the active site 
residues. Each ASP and ASH denotes un-protonated and protonated aspartates. The last 500 ps is 
highlighted with a yellow background. 
 
Table 3.1. The averaged RMSD for structures during 1000-1500 ps simulations, compared with the initial 
structure. 
   WT(Å) L90M(Å) 
   ASH25/ASP25’* ASP25/ASH25’ 
NFV All residues 
Active site residues 
1.3±0.1 
1.1±0.1 
1.3±0.1 
1.2±0.1 - 
SQV All residues 
Active site residues 
1.4±0.1 
0.8±0.1 
1.2±0.1 
0.9±0.1 
1.2±0.1 
0.8±0.1 
LPV All residues 
Active site residues 
1.0±0.1 
0.6±0.1 
1.4±0.1 
1.0±0.1 
1.2±0.1 
0.8±0.1 
PRRT All residues 
Active site residues 
1.3±0.1 
0.7±0.1 - 
1.3±0.1 
0.9±0.1 
* Each ASP and ASH denotes un-protonated and protonated aspartates. 
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Protonation States. The protonation states of the catalytic aspartates D25 and D25’ vary depending on 
the binding inhibitors or substrates.117 Hence, the appropriate protonation states of the catalytic aspartates 
should be determined for the respective ligands. For the simulations of NFV, the protonation states are 
determined in the same manner as that described in the chapter 2. That is, D25 is protonated and D25’ is 
un-protonated in each of PR(B:WT)NFV and PR(B:L90M)NFV. To determine the protonation states of 
PR(B:WT)SQV or PR(B:WT)LPV, the total energies of the two kinds of complexes are compared after 
energy minimization (Table 3.2.a). One complex represents a combination of protonated 
D25/unprotonated D25’ states, and the other represented the opposite combination. This comparison 
clearly suggests the preference of the protonated D25 and un-protonated D25’ states. In contrast to the 
case of the WT models, we apply another method to determine the protonation states of PR(B:L90M)SQV 
or PR(B:L90M)LPV because they might have greatly different conformation from the respective crystal 
structures. Hence, we execute 1.5 ns MD simulations of the two protonation states in these models and 
compared the total energies of the two protonation states for the last 500 ps of the simulations. The 
energy comparison indicates that PR(B:L90M)SQV and PR(B:L90M)LPV both prefer the protonated D25 
and un-protonated D25’ states (Table 3.2.b). For both of PR(B:WT)PRRT and PR(B:L90M)PRRT, the D25 
un-protonated and D25’ protonated states are selected so that the hydrolysis reaction can proceed as 
described in a previous paper.88 
 
Table 3.2. Determination of the protonation states of the catalytic aspartates in the SQV and/or LPV 
complex models. 
(a) WT*    (b) L90M§   
 SQV LPV   SQV LPV 
ASH25/ASP25’† 
ASH25/ASP25’ 
-115059.8‡ 
-114980.9 
-113462.6 
-113376.7 
 ASH25/ASP25’ 
ASH25/ASP25’ 
-70351.1±44.5 
-70339.9±55.2 
-69403.6±48.8 
-69377.5±51.7 
* Total energies after minimization (kcal/mol) 
† Each ASP and ASH denotes un-protonated and protonated aspartates. 
‡ Bold representation shows the energetically lower model between two. The energetically lower model was 
analyzed in this chapter. 
§ Average values and standard errors of total energies among the last 500 ps simulations (kcal/mol) 
 
Binding Energy Calculation. The binding free energy in solution is calculated with the MM_PBSA 
method by the same manner as that described in the chapter 2.  
Hydrogen Bond Criteria. The formation of a hydrogen bond is defined in terms of distance and 
orientation, as described in the chapter 2.  
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Results 
Binding Energy Calculation. The influence of L90M mutation on binding energy ?G b
  was examined 
for each ligand. Table 3.3 shows the results of MM_PBSA calculations for the WT and L90M models. 
L90M reduced the binding energies of NFV and SQV. Some experimental results have suggested that 
L90M mutation causes resistance against these inhibitors.82,51-53,82,98,100,103  On the other hand, 
PR(B:L90M)LPV exhibits almost the same affinity as that of PR(B:WT)LPV. It has been reported that the 
affinity of LPV was hardly affected by any single mutations.123 Hence, the results of our simulations are 
compatible with the results of previous experimental analyses. The affinity of PR(B:L90M)PRRT is almost 
the same as that of PR(B:WT)PRRT. 
 
Table 3.3. Binding energies of each model.* 
  ?G int
ele  ?G int
vdW  ?G sol
  ?G b
 † ??G b
 ‡ Resistant 
level§ 
NFV WT 
L90M 
-24.2±3.6 
-20.2±3.8 
-66.6±3.6 
-64.1±3.1 
37.5±3.3 
33.6±3.5 
-53.5±4.2 
-50.7±4.6 
+2.8 5 
SQV WT 
L90M 
-29.6±4.7 
-27.9±4.2 
-71.5±4.0 
-72.9±3.8 
34.7±3.6 
37.1±3.6 
-66.4±5.2 
-63.7±4.7 
+2.7 3.5 
LPV WT 
L90M 
-31.2±4.8 
-29.8±5.2 
-71.1±3.7 
-74.1±3.2 
41.0±3.4 
41.9±3.4 
-61.8±4.5 
-62.1±4.9 
-0.3 ~1 
PRRT WT 
L90M 
-74.7±9.3 
-72.4±6.3 
-84.1±4.2 
-84.7±4.7 
91.7±5.3 
89.4±4.7 
-67.2±7.5 
-67.7±5.4 
-0.5 - 
*  Energy is presented in units of kcal/mol.  
† -T?S 
  is not included.  
‡ ??G b
 
= ?G b
 (L90M)??G b
 (WT)  
§ Resistance level was taken from the references 82, 103, and 123. Resistance level is defined as 
IC90(L90M)/IC90(WT) or as IC50(L90M)/IC50(WT) in the references. 
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Hydrogen Bonds between PR and Ligand. Hydrogen bonds play an important role in stabilizing 
protein-ligand complexes. We examined 1000 snapshots during the last 500 ps and identified direct or 
one-water-molecule-mediated hydrogen bonds (Table 3.4). NFV mainly creates hydrogen bonds with 
D25’ and D30 in PR(B:WT)NFV. In contrast, NFV interacts with D25 and D25’ in PR(B:L90M)NFV. That 
is, NFV hardly interacts with D30 in PR(B:L90M)NFV. As shown in the chapter 2, D30 significantly 
contributes to PR-NFV binding and the mutation D30N causes specific resistance against NFV.82,98,99 
Moreover, in PR(B:WT)NFV and PR(B:L90M)NFV, one water molecule is located between I50/I50’ and 
NFV. This water molecule creates hydrogen bonds with I50’ of the WT PR (maintained for 99.8 % of the 
time during the last 500 ps of simulation) and with I50 of the L90M PR (92.4%), while these hydrogen 
bonds are often broken with NFV in each model (~50%). SQV has direct interaction with D25’ and 
one-water- molecule-mediated interaction with I50’ in both WT and L90M models. In addition, the main 
chain at the P2 site of SQV makes a hydrogen bond with G48 in both models. In contrast, the side chain 
at the P2 site (-CONH2) interacts with different residues in the two models. The side chain interacts with 
G48 in PR(B:WT)SQV and with D30 in PR(B:L90M)SQV. Interestingly, G48 is the residue that mutation 
causes specific resistance against SQV.99-102 Thus, both NFV and SQV lose significant hydrogen bonds 
due to L90M mutation. On the other hand, LPV has similar hydrogen bond networks in PR(B:WT)LPV and 
PR(B:L90M)LPV. LPV creates direct hydrogen bonds with D25, D25’, and D29. One water molecule 
connects LPV to the 50th residues by hydrogen bonding. In the case of PRRT, P4-P1 sites have similar 
interactions with D29, D30, and G48 in PR(B:WT)PRRT and PR(B:L90M) PRRT. However, P1’-P4’ sites of 
PRRT have different interactions. One water molecule also stays between D25/D25’ and PRRT in the PR 
model, while it hardly makes any stable hydrogen bond. 
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Table 3.4. Hydrogen bond networks in each model.  
WT L90M 
Donor Acceptor %* Donor Acceptor % 
NFV 
O3 † NFV OD1 D25’ 79.6 OD2 D25 O3 NFV 79.9 
O3 NFV OD2 D25’ 95.5 O3 NFV OD2 D25’ 99.8 
N D30 O1 NFV 81.6      
O1 NFV O D30 98.9      
SQV 
OD2 D25 O4 SQV 96.2 O4 SQV OD2 D25’ 99.7 
O4 SQV OD1 D25’ 100.0      
     N3 SQV O D30 74.6 
N2 SQV O G48 80.3 N2 SQV O G48 78.7 
N3 SQV O G48 96.0      
N I50’ O WAT207 94.4 N I50’ O WAT207 80.6 
O WAT207 O5 SQV 70.8 O WAT207 O5 SQV 75.0 
LPV 
OD2 D25 O3 LPV 96.6 OD2 D25 O3 LPV 96.7 
O3 LPV OD1 D25’ 87.3 O3 LPV OD1 D25’ 92.0 
O3 LPV OD2 D25’ 99.9 O3 LPV OD2 D25’ 100.0 
N4 LPV OD2 D25’ 98.4 N4 LPV OD2 D25’ 99.2 
N I50 O WAT206 100.0 N I50 O WAT206 94.3 
O WAT206 O2 LPV 74.7 N I50’ O WAT206 71.1 
O WAT206 O4 LPV 75.6 O WAT206 O2 LPV 99.1 
     O WAT206 O4 LPV 97.8 
N1 LPV OD2 D29 73.7 N D29 O1 LPV 95.9 
N LPV O WAT7900 81.8 N1 LPV OD2 D29 72.1 
O WAT7900 O G27 79.1      
PRRT 
OG1 T2L‡ OD2 D30 97.6 OG1 T2L  OD1 D30 86.0 
N L3L  OD2 D29 92.7 N T3L  OD2 D29 95.5 
     O WAT269 O L3L   75.6 
     O WAT269 OD1 D29 76.4 
N D29 OD1 N4L  81.2 N D29 OD1 N4L  85.0 
ND2 N4L  O D30 99.3 N D30 OD1 N4L  72.5 
N N4L  O G48 99.2 ND2 N4L  O D30 96.9 
O WAT212 O N4L  100.0 N N4L  O G48 100.0 
N I50 O WAT212 83.2 O WAT212 O N4L  76.8 
O WAT212 O I50’ 99.7 O WAT212 O P6 L  78.7 
     N I50 O WAT212 99.9 
OD2 D25’ O F5L  77.4 N F5L  O G27 96.9 
N D29’ O I7L  78.2      
N G48’ O S8L  98.9 N I50’ O S8L  86.3 
N S8L  O G48’ 99.3      
OG S8L  OD2 D29’ 90.3      
*  The listed donor and acceptor pairs satisfy the criteria for the hydrogen bond over 70 % of the 
time during the last 500 ps MD simulation. 
†  The atom names of inhibitors are shown in Figure 3.1.b. 
‡ The upper script “L” denotes the ligand. 
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Figure 3.3. 3D plots of RMSD between the average structures of the WT and L90M models. (a) Ligand 
in the L90M model is shown as colored sticks. (b) PR in the L90M model is shown in colored tube 
representation, and D25/D25’ and I84/I84’ are shown in stick representation. The color means the 
magnitude of RMSD shown in the bottom bar. In each PR, the left chain consists of P1-F99, and the right 
chain consists of P1’-F99’. The L90M model was fitted on the WT model using the coordinates of main 
chain atoms N, C?, and C of PR. The superimposed gray sticks and tubes represent the structure of the 
WT model. Each structure is drawn by the PyMOL ver. 0.99.rc6.87 
 
Comparison of Structures of the WT and L90M Models. To clarify the effect of mutation at the 90th 
residue on the conformation at active site of PR, the average structure of the L90M model for the last 500 
ps was compared with that of the corresponding WT model. The L90M model was fitted to the WT 
model using the coordinates of main chain atoms N, C?, and C, and the root-mean-squared deviation 
(RMSD) value was calculated (Figure 3.3). When the structures of each ligand in the WT and L90M 
models were compared, some atoms of NFV and SQV are found to exhibit large RMSD values (>2.0Å). 
Atoms at the thio-phenol group (-S-C6H5) in NFV are dislocated to a quite different position, and all of 
the atoms in SQV are shifted in the same direction. On the other hand, no atoms in LPV exhibit such 
large RMSD values. In the case of PRRT, the P4-P1’ sites have almost identical conformations, but there 
is  prominent difference at the P2’-P4’ sites. The tertiary structures of PR in the WT and L90M models 
were also compared. RMSD 3D plots clearly indicate that deviation in the NFV complex model is 
markedly large compared to other ligand-bound cases. In the case of NFV, main chain atoms at P79’ and 
its neighboring residues show large differences in PR(B:WT)NFV and PR(B:L90M)NFV. A flap region in 
PR(B:L90M)NFV
 also shows larger deviation from PR(B:WT)NFV. The flap region contains I50/I50’ and 
their adjacent residues. PR(B:L90M)SQV shows local conformational changes at P81 and its neighbors, so 
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called 80’s loop. In the case of LPV, the main chain atoms at the active site are hardly influenced by 
L90M mutation, although some atoms at the non-active site show large deviations. In the case of PRRT, 
the main chain atoms at I50’ and its neighbors show noticeable deviations. 
Mechanism of Conformational Changes at Active Site of PR. Figure 3.3 shows that L90M mutation 
influences the location of the ligand and the tertiary conformation of active site of PR. To determine the 
reason for induction of these conformational changes at the active site by the non-active site mutation 
L90M, conformations of the catalytic triad D25T26G27/D25’T26’G27’ have been examined in detail. 
These residues have van der Waals contacts with the side chains of the 90th residues59,67 and are located at 
the active site. In NFV, SQV, and PRRT complex models, some of the residues showed about 1.0 Å 
deviations between each WT and L90M PR (Table 3.5). On the other hand, the deviations of all of these 
residues in the LPV complex model are about 0.5 Å. These residues are the least fluctuating residues in 
PR because they create rigid hydrogen bond networks, so-called fireman grips131 (Figure 3.4). The 
root-mean-squared fluctuations (RMSF) of these residues were about 0.3 Å. Thus, these conformational 
changes at these triads are critically important. In the case of NFV, SQV, and PRRT complex models, 
D25 C? -D25’ C? distances are also different between the WT and L90M models (Table 3.6). There is 
particularly large difference in orientations of the side chains of D25/D25’. Furthermore, in the case of 
NFV and SQV, rotations occur at the side chains of I84/I84’, which are active site residues and are in 
contact with the side chains of D25/D25’ (Figure 3.5). The rotations are correlated with the changes in 
distances between D25 C? and I84 C? and between D25’ C? and I84’ C?. That is, the rotations are 
induced by displacements of the catalytic aspartates D25 and D25’. The side chains of I84/I84’ have large 
hydrophobic contacts with the ligands, and the structure of the active site is deformed asymmetrically. 
Consequently, we speculate that the following mechanism causes the active site conformational changes. 
First, L90M mutation changes the interaction between the 90th residues and D25/D25’. Second, 
D25/D25’ is shifted. Third, I84/I84’ show rotations of their side chains. Finally, the interaction between 
ligands and I84/I84’ causes conformational changes of the active site. 
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Table 3.5. Differences between RMSD values (Å) of the main chain atoms in the WT and L90M models. 
 NFV SQV LPV PRRT   NFV SQV LPV PRRT 
L23 0.4±0.5 0.2±0.5 0.7±0.5 0.2±0.5  L23’ 0.1±0.5 0.3±0.5 0.3±0.6 0.5±0.5 
L24 0.6±0.5 0.2±0.5 0.7±0.5 0.3±0.5  L24’ 0.2±0.5 0.4±0.5 0.4±0.6 0.8±0.6 
D25 0.6±0.5 0.5±0.5 0.4±0.5 0.4±0.5  D25’ 1.0±0.5 0.7±0.5 0.4±0.5 0.9±0.6 
T26 1.0±0.5 0.5±0.6 0.4±0.5 0.4±0.5  T26’ 0.9±0.6 0.9±0.6 0.2±0.5 0.7±0.5 
G27 1.1±0.6 0.6±0.6 0.4±0.6 0.8±0.6  G27’ 0.8±0.6 0.9±0.6 0.2±0.6 0.7±0.6 
A28 0.8±0.6 0.6±0.6 0.5±0.6 0.6±0.5  A28’ 0.7±0.5 0.7±0.6 0.2±0.5 0.3±0.5 
D29 0.5±0.6 0.3±0.6 0.5±0.6 0.5±0.6  D29’ 0.4±0.6 0.5±0.6 0.3±0.6 0.1±0.5 
D30 0.4±0.6 0.3±0.6 0.5±0.6 0.3±0.6  D30’ 0.4±0.6 0.4±0.6 0.3±0.5 0.2±0.6 
T31 0.4±0.5 0.3±0.5 0.4±0.5 0.1±0.5  T31’ 0.2±0.5 0.2±0.5 0.4±0.5 0.2±0.5 
V32 0.2±0.5 0.3±0.5 0.4±0.5 0.1±0.6  V32’ 0.6±0.7 0.2±0.5 0.5±0.5 0.2±0.5 
I47 0.9±0.9 0.5±0.9 1.0±0.8 0.5±0.7  I47’ >3.0±0.9 0.7±0.8 0.7±0.8 0.9±0.7 
G48 1.1±0.9 0.7±1.0 1.1±0.9 0.6±0.7  G48’ >3.0±0.9 0.8±0.9 0.7±0.8 1.3±0.8 
G49 2.0±0.9 0.4±0.9 0.7±0.8 0.9±0.8  G49’ 1.4±0.9 1.0±0.9 0.8±0.8 2.3±0.9 
I50 2.5±0.9 0.7±0.8 0.6±0.8 1.2±0.8  I50’ 1.0±0.9 0.9±0.9 1.0±0.9 1.5±0.8 
G51 2.6±1.2 0.4±0.7 0.8±0.9 2.0±1.1  G51’ 1.2±1.4 0.8±1.2 1.4±0.9 2.1±1.1 
G52 1.1±1.1 0.4±1.0 1.43±0.9 1.5±1.0  G52’ 1.6±1.5 0.7±1.0 0.7±0.9 1.7±1.0 
F53 0.8±1.0 0.5±1.0 1.84±1.0 1.1±0.9  F53’ >3.0±1.5 0.7±1.0 0.5±0.9 1.2±1.0 
P79 0.7±0.7 0.3±1.0 1.0±0.9 0.4±1.1  P79’ 2.7±1.1 0.4±0.8 0.5±0.9 0.3±0.9 
T80 0.5±0.7 0.6±1.0 0.6±0.8 0.2±0.9  T80’ 2.0±0.9 0.4±0.7 0.4±0.8 0.2±0.8 
P81 0.5±0.8 1.4±1.1 0.5±0.8 0.6±0.9  P81’ 1.4±1.0 0.4±0.8 0.3±0.9 0.2±0.9 
V82 0.5±0.7 1.1±0.9 0.7±0.7 0.4±0.8  V82’ 0.7±0.8 0.2±0.7 0.3±0.7 0.4±0.8 
N83 0.3±0.5 0.7±0.6 0.6±0.5 0.2±0.6  N83’ 0.3±0.6 0.3±0.6 0.3±0.6 0.3±0.6 
I84 0.4±0.5 0.5±0.5 0.5±0.5 0.1±0.5  I84’ 0.6±0.5 0.2±0.5 0.3±0.5 0.5±0.5 
Error ? is estimated by ? = [? (WT) 2 + ? (L90M) 2] 1/2, where ? (WT) and ? (L90M) are RMSF (Å) 
values of main chain atoms N, C?, C of each residue. RMSD that exceeds 1.2? is highlighted. 
 
 
Figure 3.4. RMSF of main chain atoms N, C? and C for the respective residue. Black lines below 
indicate the location of the catalytic triad D25T26G27/D25’T26’G27’. The catalytic triad shows the least 
fluctuation among all residues. 
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Table 3.6. Distances between D25 C?-D25’ C?, D25 C?-I84 C?, and D25’ C?-I84’ C?.* 
 D25 C?-D25’ C? NFV SQV LPV PRRT 
WT 6.2±0.1 6.7±0.2 7.1±0.2 7.3±0.3 
L90M 6.5±0.2 6.2±0.1 7.0±0.1 7.6±0.2 
?† +0.3 -0.5 -0.1 +0.3 
D25 C?-I84 C? NFV SQV LPV PRRT 
WT 5.6±0.2 5.0±0.2 4.7±0.2 4.4±0.3 
L90M 5.0±0.3 5.1±0.2 4.9±0.2 4.4±0.3 
? -0.6 +0.1 +0.2 0 
D25’ C?-I84’ C? NFV SQV LPV PRRT 
WT 4.4±0.2 5.4±0.4 5.2±0.2 5.0±0.2 
L90M 5.8±0.3 5.8±0.2 5.2±0.2 5.1±0.2 
? +1.4 +0.4 0 +0.1 
* Distances are presented in units of Å.  
† Difference between the L90 M and WT models. 
 
 
Figure 3.5. Torsion angles of N-C?-C?-C?1 of I84 (upper) and I84’ (lower) during the last 500 ps of 
simulations. Red lines represent the WT model, and green lines represent the L90M model. 
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Discussion 
In HIV-1 PR, the 90th residue is located at the dimer interface, that is, out of the 
ligand-binding pocket. Hence, it has no direct contact with any ligand of HIV-1 PR. Despite its location, 
L90M mutation causes resistance against the FDA-approved PIs, such as NFV and SQV. 13, 51-53,82,98,100,103 
It is difficult to speculate the mechanism of resistance due to L90M mutation. Several X-ray crystal 
structures have ever been provided for L90M PR.59,60,62,67 These structures showed that the side chains of 
the mutated M90/M90’ altered the interactions with the catalytic aspartates D25/D25’. Hong et al. 
determined the crystal structure of G48V/L90M HIV-1 PR in complex with SQV (labeled 
PR(B:G48V/L90M)SQV).
59 They proposed that alteration in interaction between the 90th residues and 
D25/D25’ led to reduction of structural flexibility at the main chains of the catalytic triads and lowered 
the possibility of these main chains making structural adjustments to SQV.59 Mahalingam et al. 
determined the structure of L90M PR in complex with indinavir (IDV) and with substrate analogue 
inhibitors.60,62,67 They further analyzed kinetic characteristics of L90M mutants and reported that L90M 
appeared to indirectly reduce the dimer stability. Despite the accumulation of these experimental findings, 
there has been no clear suggestion for drug designs to reduce the degree of or prevent the drug resistance 
due to L90M. 
In this chapter, investigations of L90M PR were carried out to suggest the multi-drug resistant 
mechanism due to L90M, and the structures of L90M PR in complexes with NFV, SQV, LPV, and a 
substrate at the PR/RT cleavage site (PRRT) were analyzed in detail. NFV and SQV reduce their 
inhibitory efficacy due to L90M mutation.82,98,100-103 In contrast, LPV hardly changes its affinity with PR 
despite a single L90M mutation.123 The substrate PRRT has a unique sequence, Phe-Pro, at P1/P1’ sites, 
whose structure is the basis for the drug design for NFV, SQV, and other PIs.77,78 In all computed models, 
changes in interaction between the catalytic aspartates D25/D25’ and the 90th residues occur due to the 
L90M mutation. In contrast, different responses have been observed at active site of PR in the models. In 
PR(B:L90M)NFV, L90M causes large conformational changes at the active site, and especially at flap and 
80’s loop regions of PR (Figure 3.6). The flap region consists of I50/I50’ and their neighboring residues. 
The 80’s loop is composed of P79-P81 or P79’-P81’. The L90M mutation also causes dislocations of the 
side chains of D25/D25’ and rotations of the side chains of I84/I84’. In PR(B:L90M)SQV, a positional shift 
of SQV and local conformational change at the 80’s loop regions occur. Dislocations of the side chains of 
D25/D25’ and rotations of I84/I84’ also occur, as observed in PR(B:L90M)NFV. These conformational 
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changes have also been observed in the crystal structure of PR(B:G48V/L90M)SQV (PDB code: 1FB7
82) 
when compared with the crystal structure of PR(B:WT)SQV (PDB code: 1HXB
77,89) (Figure 3.7). In 
addition, a comparison of the predicted structure of PR(B:L90M)SQV and the crystal structure of 
PR(B:G48V/L90M)SQV shows that the 80’s loop, where L90M causes conformational changes, is located 
at similar positions in the two structures (Figure 3.7). In the complex with each of these two inhibitors, 
the L90M mutation induces common effects: dislocations of the 25th residues and rotations of the side 
chains of the 84th residues. In addition, L90M PR decreases the binding energy with each of NFV and 
SQV, which would reflect the positional shift of the inhibitors. In contrast, in PR(B:L90M)LPV, 
conformational changes hardly occur at the active site. Dislocations of the 25th residues and rotations of 
the side chains of the 84th residues hardly appear. Energetically, LPV exhibits the same binding affinity 
with L90M and WT PRs. PRRT also exhibits the same affinity with L90M and WT PRs, although 
conformations at both of the residues near I50/I50’ and P2’-P4’ sites of PRRT are greatly changed. In the 
PRRT model, no rotation of the side chains of I84/I84’ occurs, while the distance between the two side 
chains of D25 and D25’ is changed. These results indicate that rotations of the side chains of I84/I84’ are 
involved in resistance due to L90M. Consequently, we can conclude that the mechanism of resistance due 
to L90M is rotations of the side chains of the 84th residues due to dislocations of the side chains of the 
25th residues, which are initiated by changes in interaction between the 90th and the 25th residues. These 
rotations change the shapes of the active sites, and the change decreases the interactions between HIV-1 
PR and ligands (Figure 3.8).  
There is still the question of why rotation of the 84th side chains occurs when L90M PR is 
bound with NFV or SQV but does not occur when L90M PR is bound with LPV and PRRT. It is 
considered that the rotations is due to not only to dislocations of the side chains of D25/D25’ but also to 
the geometry of ligand. The shift of the side chains of D25/D25’ occurs when L90M PR is bound with 
NFV, SQV, and PRRT. Focusing on the P1/P1’ sites of those ligands, NFV and SQV each contains a 
rigid and bulky dodecahydroisoquinoline ring, and PRRT has a ring of Pro. These rings are located near 
D25/D25’ and assist the dislocation of the side chains of D25/D25’ because of their rigidity. Moreover, 
the size of the ring is responsible for the rotation of the side chains of I84/I84’. Rotation of the side chains 
of the 84th residues occurs when L90M PR is bound with NFV or SQV. In contrast, rotation hardly 
occurs despite the side chain dislocations of D25/D25’ when L90M PR is bound with PRRT. The ring 
size of PRRT is smaller than those of NFV and SQV and makes no unfavorable collision with the side 
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chains of I84/I84’. Consequently, the size and flexibility of the P1/P1’ sites of ligand are closely related 
to resistance due to L90M. We speculate that a single L90M mutation has little effect on the binding 
affinity with a ligand that has a linear group or a small ring at its P1/P1’ sites. 
 
Figure 3.6. Structures (a) at the surrounding region of the 90th residue and (b) at the flap region. 
PR(B:WT)NFV is represented by white tubes, and PR(B:L90M)NFV is represented by blue tubes. Each 
structure is drawn by the PyMOL ver. 0.99.rc6.87 
 
 
Figure 3.7. 3D plots of RMSDs (a) between the crystal structures of PR(B:WT)SQV
77,89
 and 
PR(B:G48V/L90M)SQV
82 and (b) between the average structure of PR(B:L90M)SQV and the crystal structure 
of PR(B:G48V/L90M)SQV.
82 In each PR, the left chain consists of P1-F99, and the right chain consists of 
P1’-F99’. Color indicates the magnitude of RMSD shown at the right bar. The structures were superimposed 
using the coordinates of main chain atoms N, C?, C of PR. Each structure is drawn by the PyMOL ver. 
0.99.rc6.87 
 
 
Figure 3.8. Structure around the active site. Each PR in the L90M model is shown in green cartoon, and 
each of the ligands and important residues is shown in green ball-and-stick representation. The 
superimposed gray cartoons and sticks represent the structure of the WT model. Each structure is drawn 
by the PyMOL ver. 0.99.rc6.87 
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 We further investigated the interactions between the ligands and each amino acid residue of 
PRs by performing fragment molecular orbital (FMO) calculations.132 In the FMO scheme, the total 
system is divided into fragments and calculations are carried out in parallel, which makes it possible to 
adopt the ab initio MO calculation for a large molecule like a protein. The single point energy of each 
model was calculated at the FMO-HF/6-31G level using the ABINIT-MP program.133 The model 
structures were constructed by the following two steps. First, the average structure was calculated on the 
basis of 1000 coordinates acquired during the last 500 ps of MD simulation. Next, energy minimization 
was executed on the average structure. One amino acid residue or one inhibitor was set as a single 
fragment. It was confirmed from the computational results that each of the ligands indeed interacts with 
the active site residues or their neighboring residues (Figure 3.8). Notably, LPV and PRRT interact with 
only several active site residues. That is, the residues they interact with are quite limited compared with 
those with which NFV and SQV interact. Furthermore, LPV shows no significant difference between its 
interactions in WT and L90M PRs. LPV has highly specific interactions with D29 and D25’, whose 
mutations inactivate the function of HIV-1 PR.75,134 The results also indicates that NFV and SQV show 
noticeable loss of interaction energies with several residues in both the WT and L90M models. In 
particular, NFV has unfavorable contact with K45, R87, R8’, D29’, and D30’, and SQV has unfavorable 
contact with D25’ and D29’. In contrast, LPV shows little energetical loss in interaction with protein 
residues in both models. Hence, we speculate that this specificity and the little energetical loss are also 
reasons why L90M mutation has little effect on the binding of LPV. 
 
 
Figure 3.8. Inter-residue interaction energies between PR and ligand calculated by the FMO-HF/6-31G. 
Black lines below indicate the location of the active site residues (R8, L23-V32, I47-I50, P81-I84, R8’, 
L23’-V32’, I47’-I50’, P81’-I84’). 
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In this chapter, the mechanism of resistance due to the non-active site mutation L90M has 
been clarified through theoretical calculations. The 90th residue of HIV-1 PR is located at the dimer 
interface and has no direct contact with ligand chemicals. The simulations demonstrate that the non-active 
site mutation L90M influences conformation of the binding cavity and ligand-binding affinity at active 
site of PR. To the best of our knowledge, this is the first report to suggest that the non-active site resistant 
mutation influence binding with inhibitors at the active site. Furthermore, we suggest that design of PI 
that maintains the efficacy toward L90M mutant PR. 
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Chapter 4 
Resistant Mechanism against NFV 
 due to N88S in HIV-1 PR 
 
 
 
 
 
 - 43 -
Introduction 
 This chapter shows the resistant mechanism against nelfinavir (NFV) due to N88S in HIV-1 
protease (HIV-1 PR), through computational simulations (Figure 4.1). N88S is often observed in patients 
with CRF01_AE HIV-1 for whom treatment with NFV has failed.46 In contrast, N88S is rarely seen in 
those with subtype B HIV-1. The majority of CRF01_AE HIV-1, so called subtype AE HIV-1, is 
epidemic in South Asia (Figure 1.1). However, it has not been clarified why the emergence of N88S in 
subtype AE PR confers resistance against NFV. Since N88S occurs at non-active site of HIV-1 PR, it is 
difficult to speculate on the mechanism of the resistance. Subtype AE HIV-1 PR has natural 
polymorphisms, K20R, E35D, M36I, R41K, H69K, L89M, and I93L, in PR unlike subtype B PR. These 
polymorphisms are also located at non-active site of PR. It is still uncertain how the polymorphisms 
influence structure of PR. We also examine the difference of structures between the subtype B wild-type 
(WT) PR and the subtype AE reference PR. 
 
 
Figure 4.1. (a) X-ray crystal structure of the complex of HIV-1 PR and NFV.94 The PR has two identical 
polypeptide chains, each of which consists of 99 residues P1-F99 and P1’-F99’. Locations of the two 
catalytic aspartates D25/D25’, D30 and N88, are shown in ball and stick representation. Locations of 
polymorphisms in subtype AE PR (K20R, E35D, M36I, R41K, H69K, L89M, and I93L) are shown in 
stick representation. The structure is drawn by the PyMOL ver. 0.99.rc6.87 (b) Hydrogen bond network 
between PR and NFV in the crystal structure.94 (c) Chemical structure of NFV. (d) The amino acid 
sequences of the subtype B wild-type (WT) HIV-1 PR (HXB2) and the reference sequence of subtype AE 
HIV-1 PR (NH1). The polymorphisms in subtype AE PR are highlighted in red letters. 
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Materials and Methods 
Force Field Parameters. Before carrying out molecular dynamics (MD) simulations, we improved 
torsional force field parameters for benzamide: CA-CA-C-N and CA-CA-C-O. The benzamide group 
comprises a part of NFV. The improved torsional parameters are generated in the same manner as that for 
the development of the AMBER ff03 force field135 (Figure 4.2). First, the restrained electrostatic potential 
(RESP) charges111 of benzamide are determined on the basis of data from quantum mechanical (QM) 
calculations. Geometric optimization of benzamide is performed at the HF/6-31G(d,p) level, and the 
electrostatic potential is calculated at the B3LYP/cc-pVTZ level under solvation condition with ether 
(?=4) by the IEFPCM method using the Gaussian 03 program.127 The partial atom charges are determined 
using the RESP method so that the atom charges can reproduce the values of the calculated electrostatic 
potential at the surrounding points of benzamide. Charges are equalized between two atoms if they are the 
same element and had the same bond coordination. Second, the potential energy curve is obtained by 
repeating energy calculations with 5.0 degree stepwise changes in the torsional angle for CA-CA-C-N in 
benzamide. Energy calculations are executed at the MP2/cc-pVTZ level in the ether phase after geometric 
optimizations at the HF/6-31G(d,p) level. Third, the torsional parameters are obtained by the discrete 
Fourier transform of the potential energies from QM calculations. The torsional parameter for 
CA-CA-C-O is assumed to be equal to that for CA-CA-C-N.  
Furthermore, the RESP charges for NFV are determined in the same manner as that described 
above. 
 
Figure 4.2. Parameter development for torsion of benzamide: CA-CA-C –N and CA-CA-C- O. Chemical 
structure of benzamide is shown left and atom types are labeled. Potential energy profile is shown right. 
Open squares show QM energies of geometry optimized structures at the HF/6-31G(d,p) level. Closed 
squares show QM energies at the MP2/cc-pVTZ level under the ether-solvated condition after geometry 
optimizations at the HF/6-31G(d,p) level. Red solid line shows potential energy surface of the presently 
developed force field parameters. Green solid line shows that of the AMBER ff03 force field. 
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Molecular Dynamics (MD) Simulations. Minimizations and MD simulations are carried out using the 
sander module of the AMBER 8 package.108,136 The AMBER ff03 force field135 is used as the parameters 
for proteins, ions, and water molecules. The general AMBER force field128 and the newly developed force 
field are used as the parameters for NFV. We examine the structure of each of the three PRs in complex 
with NFV: the reference (Ref) PR, N88S PR of subtype AE HIV-1 in complex with NFV (PR(AE:Ref)NFV 
and PR(AE:N88S)NFV); the wild-type (WT) PR of subtype B HIV-1 with NFV (labeled PR(B:WT)NFV). 
We use NH1 as the reference sequence of subtype AE HIV-1137 and use HXB2 as the WT sequence of 
subtype B HIV-1. Each initial structure for these PRs in complex with NFV is modeled from the atom 
coordinates of an X-ray crystal structure (PDB code 1OHR)94 using the LEaP module. Each model is 
placed in a rectangular box filled with about 8000 TIP3P water molecules,112 with all of the crystal water 
molecules remaining. The expansion and shrinkage of all covalent bonds connecting to hydrogen atoms 
are constrained using the SHAKE algorithm.113 The periodic boundary conditions114-116 are applied to 
avoid the edge effect in all calculations. When using the periodic boundary condition, particles are 
enclosed in a box, and we can imagine that the box is replicated to infinity by translation in all the three 
cartesian directions, completely filling the space. The particle mesh Ewald method114-116 is applied to 
compute long-range interaction energy under the periodic boundary condition. The cutoff distance for the 
long-range electrostatic and the van der Waals energy terms is set to 12.0 Å. Energy minimization is 
achieved in three steps. First, movement is allowed only for water molecules and ions. Next, NFV and the 
mutated residues are allowed to move in addition to the water molecules and ions. Finally, all atoms are 
permitted to move freely. In each step, the energy minimization is executed by the steepest descent 
method for the first 10000 steps and the conjugated gradient method for the subsequent 10000 steps. 
After 0.1 ns heating calculation until 310 K using the NVT ensemble, 3.0 ns equilibrating calculation is 
executed at 1 atm and at 310 K using the NPT ensemble, with an integration time step of 2.0 fs. In the 
present calculations, the MD simulations show no large fluctuations after about 2.0 ns of equilibrating 
calculations (Figure 4.3 and 4.4). Hence, atom coordinates are collected at an interval of 1.0 ps for the last 
1.0 ns to analyze the structure in detail. 
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Figure 4.3. RMSD plot during MD simulations about each PR. RMSD were calculated from the 
coordinates of main chain atoms N, C?, C. The residues at codon 8, 23-32, 47-50, 81-84 are selected as 
the active site residues. Each ASP and ASH denotes un-protonated and protonated aspartates. The last 1.0 
ns is highlighted with a yellow background.  
 
Figure 4.4. Principal component analyses (PCA) of the whole trajectory during 3.0 ns MD simulation. 
Red and green dots correspond to 0.0-2.0 ns, and 2.0-3.0 ns trajectories. Judging from the 2.0-3.0 ns 
trajectory, the PR-NFV complexes were regarded to be in the equilibrium state. 
 
The protonation states of the catalytic aspartates D25 and D25’ vary depending on sequence 
of HIV-1PR or the binding ligand.117 Hence, the appropriate protonation states of the catalytic aspartates 
should be determined for each model. Because NFV mimics a transition state of catalytic reaction by 
HIV-1 PR, we considered two kinds of the protonation states.77,89,129 One is a combination of protonated 
D25 and un-protonated D25’ states, and the other is the opposite combination. In order to determine the 
protonation states when NFV binds to each PR, the absolute free energies of the complexes with these 
two kinds of the protonation states are compared using the calculation data obtained during 2.0-3.0 ns of 
MD simulations. The free energies are calculated on the basis of the MM_PBSA method.138,139 We use the 
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same parameter set for the electrostatic and van der Waals energy terms as that used in the MD 
simulations, and no cutoff is applied for the calculation. Since the dielectric constants for the interior of 
proteins are considered to be in the range of 2-4, the interior dielectric constant is set to 2.0.140 The outer 
dielectric constant is set to 80.0. The pbsa program was used to solve the Poisson-Boltzmann (PB) 
equation. All three models (PR(AE:Ref)NFV, PR(AE:N88S)NFV, and PR(B:WT)NFV) preferred the 
combination of un-protonated D25 and protonated D25’ (Table 4.1). 
 
Table 4.1. Determination of the protonation states of D25/D25’ in each PR complexed with NFV. 
 AE:Ref AE:N88S B:WT 
ASH25/ASP25’ * 1936.7±38.1 1953.1±39.6 1964.9±40.4 
ASP25/ASH25’ 1922.9±39.6†,‡ 1951.5±38.4 1957.6±42.3 
Energy is presented in units of kcal/mol. 
*  Each ASP and ASH denotes un-protonated and protonated aspartates. 
†  Bold representation shows the energetically lower model between two. The energetically lower 
model was analyzed in this chapter. 
‡  The free energy of complex are positive because highly positive internal interaction energies and 
slightly negetive solvation energies. The absolute value of the total free energy, however, has no 
significant meaning. Instead, the difference in energy should be paid attention to. 
PR(B:WT)NFV-ASP25/ASH25’ Complex Receptor Ligand Delta 
G int
ele  -1143.4 -1114.8 -16.1 -12.5 
G int
vdW  -813.9 -757.4 15.4 -71.8 
G int
  4392.1 4298.0 94.1 0.0 
G int
ele
+G int
vdW
+G int  2434.8 2425.7 93.3 -84.3 
G sol
 (PBSA) -477.2 -489.2 -3.1 15.1 
G b
 (MM_PBSA)  1957.6 1936.5 90.3 -69.2 
G sol
 (GBSA)  -464.8 -469.9 -1.6 6.7 
G b
 (MM_GBSA)  1970.0 1955.8 91.7 -77.6 
Energy is presented in units of kcal/mol. Gint denotes the internal energies which include energies of 
bond stretching, angle bending, and tortional rotations.  
 
 
Hydrogen Bond Criteria. The formation of a hydrogen bond is defined in terms of distance and 
orientation, as described in the chapter 2. 
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Binding Free Energy Calculation. The binding free energy120 is calculated with the MM_PBSA method 
by the following equation: 
?Gb = ?Gintele + ?GintvdW + ?Gsol ? T?S , 
where ?Gb  is the binding free energy in solution, ?Gint
ele and ?GintvdW  are the electrostatic and van der 
Waals interaction energies between a ligand and a protein, ?Gsol  is the solvation energy, and ?T?S  is 
the contribution of conformational entropy to the binding. In this study, assuming that the contribution of 
conformational entropy to the change in ?Gb  is negligible among mutants,
141 we neglect the entropy 
term in the energy estimation. ?Gintele and ?GintvdW  are computed using the same parameter set as that 
used in the MD simulation, and no cutoff is applied to the calculation. The solvation energy ?Gsol  is 
calculated using the pbsa program. The interior dielectric constant is set to 2.0, and the outer dielectric 
constant is set to 80.0.140 The pbsa program is used to solve the PB equation.  
Furthermore, the contribution of each residue to the binding free energy is calculated. The 
total binding free energy is decomposed into the contribution from each individual residue by the 
MM_GBSA method. The modified GB model developed by Onufriev, Bashford, and Case142 is used to 
calculate the solvation energy term. To ascertain whether or not the MM_GBSA results are consistent 
with the MM_PBSA results, we compared the total binding free energy obtained by the MM_PBSA 
method with that obtained by the MM_GBSA method for all coordinates acquired through the MD 
simulation. The MM_GBSA results are confirmed to be highly correlated with the MM_PBSA results 
(correlation coefficient r ? 0.998) (Figure 4.5). 
 
Figure 4.5. Correlation between energies based on the MM_PBSA method and those by the 
MM_GBSA method. Binding free energies were calculated for 3000 sets of atom coordinates. These 
energies are plotted with red dots, and an approximated line is drawn in grey. 
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Results 
Reconsideration of Torsional Force Field Parameters for Benzamide. Before carrying out MD 
simulations, we reconsidered torsional force field parameters for benzamide: CA-CA-C-N and 
CA-CA-C-O (Figure 4.2). The benzamide group comprises a part of NFV. The benzamide moiety in 
NFV has an important interaction with D30 of PR.94 Nevertheless, AMBER force fields such as the 
ff03135 and general AMBER force fields128 cause much higher energy barrier around the rotatable bond 
between the benzene and amide groups in benzamide than that based on QM calculations (Figure 4.2). 
This may cause serious problem for our simulations. The force field parameters for benzamide need to be 
carefully examined and preferably changed from the original AMBER force fields, as described in the 
AMBER Archive in 2003.143 The torsional parameters were generated in the same manner as that for the 
development of the AMBER ff03 force field. The obtained parameters are listed in Table 4.2. We 
executed MD simulations using these newly developed force field parameters. 
 
Table 4.2. Torsional force field parameters for the benzamide part of NFV.* 
CA-CA-C- N  CA-CA-C-O 
Vn/2 n ?  Vn/2 n ? 
Developed parameters 
0.90 
0.05 
2 
4 
180.0 
0.0 
 0.90 
0.05 
2 
4 
180.0 
0.0 
AMBER ff03 force field 
3.68 2 180.0  3.63 2 180.0 
* Tortion energy is given by E = ?(Vn/2)[1 + cos(n? – ?)]. 
 
Hydrogen Bonds between NFV and PRs. Hydrogen bonds play an important role in protein-ligand 
bindings. First, we examined hydrogen bonds between NFV and PR in each complex: PR(AE:Ref)NFV, 
PR(AE:N88S)NFV, and PR(B:WT)NFV. We examined 1000 snapshot structures for the last 1.0 ns and 
identified direct or one-water-molecule mediated hydrogen bonds (Figure 4.6 and Table 4.3). All three 
PRs create similar hydrogen bond networks. The side chains of both D25 and D25’ interact with the 
central hydroxyl group of NFV (the atom corresponding to O3 in Figure 4.1.c). One water molecule 
mediates the interaction between the main chains of I50/I50’ and NFV. Furthermore, another water 
molecule mediates the interaction between D29’ and NFV. However, the interaction between NFV and 
the 30th residue has variations among the three PRs. In PR(AE:Ref)NFV and PR(B:WT)NFV, either the main 
chain or the side chain of D30 makes direct hydrogen bonds with NFV (Figure 4.7). On the other hand, 
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PR(AE:N88S)NFV mainly creates one-water-molecule-mediated hydrogen bonds between the main chain 
of D30 and NFV. 
 
 
Figure 4.6. Snapshot of hydrogen bond networks at the active site in MD simulations of each model. 
Tertiary structure of each model is shown in cartoon representation. D25/D25’, D30, D29’, D30, and 
I50/I50’ are shown in sticks. Water molecules related to hydrogen bonds are shown in spheres. Each 
structure is drawn by the PyMOL ver. 0.99.rc6.87 
 
Table 4.3. Hydrogen bond networks between NFV and PR residues in each model. 
(a) D25/D25’ 
Donor Acceptor %* Donor Acceptor % 
AE:Ref B:WT 
O3† NFV OD1 D25 96.1 O3 NFV OD1 D25 82.8 
O3 NFV OD2 D25 98.5 O3 NFV OD2 D25 99.8 
OD2 D25’ O3 NFV 100.0 OD2 D25’ O3 NFV 100.0 
AE:N88S  
O3 NFV OD1 D25 70.9      
O3 NFV OD2 D25 99.1      
OD2 D25’ O3 NFV 100.0      
(b) I50/I50’ 
Donor Acceptor % Donor Acceptor % 
AE:Ref B:WT 
O WAT209 O2 NFV 98.5 O WAT207 O2 NFV 98.5 
O WAT209 O4 NFV 92.6 O WAT207 O4 NFV 90.5 
N I50 O WAT209 81.5 N I50 O WAT207 94.7 
N I50’ O WAT209 97.2 N I50’ O WAT207 97.7 
AE:N88S  
O WAT209 O2 NFV 91.2      
O WAT209 O4 NFV 95.4      
N I50 O WAT209 76.8      
N I50’ O WAT209 97.2      
(continued to the next page) 
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Table 4.3. (continued) 
(c) D29’ 
Donor Acceptor % Donor Acceptor % 
AE:Ref B:WT 
N3 NFV O WAT4056 29.8 N3 NFV O WAT4033 25.9 
N D29’ O WAT4056 27.2 N D29’ O WAT4033 23.5 
O WAT4056 OD1 D29’ 21.9 O WAT4033 OD1/OD2 D29’ 25.3 
N3 NFV O WAT4716 12.6 N3 NFV O WAT6585 47.6 
N D29’ O WAT4716 11.6 N D29’ O WAT6585 44.8 
O WAT4716 OD1 D29’ 5.5 O WAT6585 OD1/OD2 D29’ 36.9 
N3 NFV O WAT6480 16.7 N3 NFV O WAT7627 18.8 
N D29’ O WAT6480 14.9 N D29’ O WAT7627 17.6 
O WAT6480 OD1 D29’ 14.8 O WAT7627 OD2 D29’ 5.5 
AE:N88S  
N3 NFV O WAT4441 61.8      
N D29’ O WAT4441 54.1      
O WAT4441 OD1/OD2 D29’ 59.0      
N3 NFV O WAT6151 26.2      
N D29’ O WAT6151 22.9      
O WAT6151 OD1/OD2 D29’ 22.9      
(d) D30 
Donor Acceptor % Donor Acceptor % 
AE:Ref B:WT 
N D30 O1 NFV 5.7 N D30 O1 NFV 30.7 
O1 NFV OD1/OD2 D30 69.2 O1 NFV OD1/OD2 D30 31.6 
O1 NFV O D30 9.0 O1 NFV O D30 42.9 
AE:N88S  
N D30 O1 NFV 7.4      
O1 NFV O D30 27.9      
O1 NFV O WAT6715 28.8      
N D30 O WAT6715 28.3      
O WAT6715 N D30 12.6      
O WAT6715 O D30 31.8      
O1 NFV O WAT7886 13.6      
O WAT7886 OD1 D30 5.2      
O WAT7886 O D30 25.5      
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
† The atom names of NFV are shown in Figure 4.1.c. 
 
 
Figure 4.7. Distance between NFV and the 30th residue. Each red and green solid line corresponds to the 
distance between N of the 30th residue and the O1 atom of NFV and to the distance between O of the 
30th residue and the O1 atom of NFV. Blue solid lines show the distances between O1 of NFV and 
OD1/OD2 of D30. 
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Hydrogen Bonds of the Side Chain of the 30th Residue with PR Residues. In PR(AE:N88S)NFV, the 
side chain of the 30th residue does not create any hydrogen bonds with NFV. To clarify the effects of the 
N88S mutations in detail, the interactions of the side chain of the 30th residue with the other residues of 
PR were investigated (Table 4.4). PR(AE:Ref)NFV and PR(B:WT)NFV have an interaction between the side 
chains of D30 and K45. The side chains of D30 in PR(AE:N88S)NFV have either a direct hydrogen bond 
with the side chain of S88 or one-water-molecule-mediated hydrogen bonds with T31 and T74. In 
PR(AE:Ref)NFV and PR(B:WT)NFV, T31, T74, and N88 also create hydrogen bond networks at the 
non-active sites although D30 is not involved in the networks (Table 4.5). The mutation N88S affects 
those hydrogen bond networks. 
 
Table 4.4. Hydrogen bond networks of the side chain of D30 or N30 with PR residues. 
Donor Acceptor %* Donor Acceptor % 
AE:Ref B:WT 
NZ K45 OD1 D30 38.3 NZ K45 OD1/OD2 D30 67.0 
AE:N88S  
OG S88 OD2 D30 77.8      
O WAT226 OD2 D30 33.7      
OG1 T31 O WAT226 18.1      
N T31 O WAT226 31.4      
O WAT226 O T74 33.8      
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
 
Table 4.5. Hydrogen bond networks around N88 or S88 in each PR. 
Donor Acceptor %* Donor Acceptor % 
AE(Ref) B(WT) 
N T31 OD1 N88 86.7 N T31 OD1 N88 86.7 
OG1 T31 OD1 N88 96.1 OG1 T31 OD1 N88 96.1 
ND2 N88 O WAT222 10.4 ND2 N88 O WAT220 68.8 
N T31 O WAT222 12.1 N T31 O WAT220 65.7 
ND2 N88 O WAT5506 19.4 O WAT220 O T74 72.7 
N T31 O WAT5506 22.3 O WAT220 O T31 71.6 
O WAT5506 O T31 22.7 O N88 O WAT5693 55.4 
O WAT5506 O T74 23.6 ND2 N88 O WAT5693 23.7 
ND2 N88 O WAT2775 11.3 N T74 O WAT5693 68.9 
N T74 O WAT2775 11.0      
ND2 N88 O WAT4739 15.9      
N T74 O WAT4739 14.3      
AE(N88S)  
N S88 O D29 98.0      
OG S88 OD2 D30 77.8      
O WAT6219 OG S88 29.8      
O WAT6219 OD1 D29 25.9      
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
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Comparison of the Structures with PR(AE:Ref)NFV. To clarify the effects of mutations at the 88th 
residues on active site conformations of PR, the average structure of each model for the last 1.0 ns was 
compared with that of PR(AE:Ref)NFV. Each model was fitted to PR(AE:Ref)NFV using the coordinates of 
main chain atoms N, C?, and C, and the root mean squared deviation (RMSD) value was calculated 
(Figure 4.8). When active site residues of each PR are compared with those of PR(AE:Ref)NFV, 
conformational changes are observed only on the active site residues around the 30th residue. 
PR(AE:N88S)NFV shows large conformational change at D30 (RMSD = 1.1±0.4 Å). Next, we compared 
the location of NFV in each model with that of PR(AE:Ref)NFV. The m-phenol group of NFV, which 
interacts with the 30th residue, shows larger positional deviation than the other parts of NFV. On the 
other hand, PR(B:WT)NFV shows slight conformational change at the active site residues and NFV. 
 
Figure 4.8. 3D plot of RMSD of the average structure of each model from that of PR(AE:Ref)NFV. (a) PR 
in each model is shown in colored tube representation. In each PR, the left chain consists of P1-F99 and 
P1’-F99’. (b) NFV in each model is shown in color stick representation. The color refers to the magnitude 
of RMSD shown in the right bar. Each model was fitted to PR(AE:Ref)NFV using the coordinates of main 
chain atoms N, C?, and C of PR. The superimposed gray sticks and tubes represent the structure of 
PR(AE:Ref)NFV. Each structure is drawn by PyMOL ver. 0.99.rc6.
87 
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Binding Free Energy Calculations. The influence of the mutation or the polymorphisms on the binding 
free energy ?Gb was examined for each model. The results show that PR(AE:N88S)NFV largely reduces 
the binding energy with NFV, compared with that of PR(AE:Ref)NFV (Table 4.6). On the other hand, 
PR(AE:Ref)NFV has binding affinity similar to PR(B:WT)NFV. We also investigated the contributions of 
the respective residues to binding free energy (Figure 4.9). In all three models, the active site residues 
stabilize the complex of each PR and NFV. It should be noticed that PR(AE:N88S)NFV reduces the 
contribution to the binding energy due to D30 compared with PR(AE:Ref)NFV. 
 
Table 4.6. Binding free energy of each model. 
  ?G int
ele  ?G int
vdW  ?G sol
  ?G b
 * ??G b
 † 
AE:Ref  -12.8±1.7 -70.8±4.0 15.1±1.5 -68.6±3.7 - 
AE:N88S  -10.6±1.4 -67.8±4.0 12.8±1.9 -65.6±3.9 3.0 
B:WT  -12.5±1.4 -71.8±3.8 15.1±1.4 -69.2±3.7 -0.6 
Energy is presented in units of kcal/mol. 
* -T?S 
 is not included. 
† Difference from PR(AE:Ref)NFV. 
 
 
Figure 4.9. (a) Contribution of the individual residues to binding free energy between PR and NFV. The 
energetic contributions of the residues are shown in red solid lines, and those of PR(AE:Ref)NFV in green 
lines. (b) Difference in contribution of the individual residues to the binding energy between each model 
and PR(AE:Ref)NFV. The bottom black lines indicate the locations of the active site residues (R8, L23-V32, 
I47-I50, P81-I84, R8’, L23’-V32’, I47’-I50’, P81’-I84’). 
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Discussion 
In this chapter, we performed MD simulations of HIV-1 PRs in complex with NFV for the 
purpose of clarifying (1) the mechanism of resistance against NFV due to N88S in subtype AE PR, and 
(2) the difference of structures between PR(B:WT)NFV and PR(AE:Ref)NFV. 
It has been reported that the emergence of N88S mutation is highly related to resistance 
against NFV.82,104,105 However, since the 88th residue is located at non-active site of HIV-1PR, it is 
difficult to speculate on the mechanism of resistance due to N88S. Our simulations indicate that 
PR(AE:N88S)NFV has lower affinity with NFV than PR(AE:Ref)NFV does, owing to the following 
mechanism. First, a hydrogen bond between the side chain of D30 and the side chain of S88 is created 
(Figure 4.10). Second, the location of D30 is changed. Finally, the interaction between D30 and NFV is 
reduced. N88S indirectly influences the binding between NFV and D30. The interaction with D30 is an 
essential factor for NFV binding. The mutation D30N in subtype B PR also confers specific resistance 
against NFV,82,98,99 because the electrostatic interactions between NFV and the 30th residue are largely 
reduced, as described in the chapter 2. Accordingly, N88S confers specific resistance against NFV. In 
contrast, it is interesting that amprenavir (APV), which is another FDA-approved PI, shows 
hypersensitivity toward N88S PR.103 According to a crystal structure of PR with APV,92 APV does not 
create hydrogen bonds with D30 in PR, but those with D29. Therefore, the efficacy of APV will be 
maintained toward N88S mutants. By the way, N88D is another frequently observed mutation at the 88th 
residue of PR. As shown in the chapter 2, N88D also changes the interactions of the 88th residue with the 
30th, 31st and 74th residues. However, N88D does not cause resistance against NFV, but stabilizes 
binding of PR with NFV. N88S changes the interactions in a manner different from that of N88D. 
 
Figure 4.10. Hydrogen bond networks around N88 or S88 of PR: (a) hydrogen bond networks in 
PR(AE:Ref)NFV and PR(B:WT)NFV; (b) those in PR(AE:N88S)NFV. Each structure is drawn by the PyMOL 
ver. 0.99.rc6.87 
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 We also investigated the difference of structures between PR(AE:Ref)NFV and PR(B:WT)NFV. 
Subtype AE PR has natural polymorphisms: K20R, E35D, M36I, R41K, H69K, L89M, and I93L, unlike 
subtype B PR. It is reported that some of the polymorphisms are related to resistance against PIs,13 
although they appear at non-active site of PR. Hence, it is not clear whether or not the polymorphisms 
influence binding with ligands. The results indicate that the polymorphisms in subtype AE PR hardly 
influences conformation of active site of PR and binding of NFV, although large change of conformation 
is observed at non-active site of PR. The only but slight difference that we can find is the interactions 
between D30 of PR and NFV (Figure 4.7). In PR(B:WT)NFV, either of the main chain or the side chain of 
D30 have hydrogen bonds with NFV. On the other hand, in PR(AE:Ref)NFV, the side chain of D30 mainly 
creates hydrogen bonds with NFV. The slight change of the interactions might influence the emergence 
rate of N88S between subtypes. We confirm this hypothesis in the next chapter. 
 Prior to the MD simulations, we reconsidered torsional force field parameters for the 
benzamide moiety in NFV. This moiety has essential hydrogen bonds with D30 of HIV-1 PR.94 Thus, 
those torsional parameters are expected to greatly affect the results of the simulations. Nevertheless, 
AMBER force fields such as the ff03135 and general AMBER force fields128 cause much higher energy 
barrier around the rotatable bond between the benzene and amide groups in the benzamide than that of 
QM calculations (Figure 4.2). This may cause serious problem for our simulations. Therefore, we 
improved the torsional force field parameters for the benzamide moiety in NFV on the basis of the energy 
curve obtained from QM calculations. Our newly developed parameters enable us to carry out precise 
simulations of HIV-1 PR in complex with NFV. 
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Chapter 5 
Polymorphisms Associated with  
Emergence of Drug-resistant Mutations 
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Introduction 
In the chapter 5, we examine whether or not polymorphisms in non-subtype B HIV-1 protease 
(HIV-1 PR) influence emergence rate of drug-resistant mutations. Recently, Ariyoshi et al. reported that 
the pattern of drug-resistant mutations differed between subtype B and CRF01_AE (subtype AE) 
HIV-1.46 Mutations of L10F, K20I, L33I, and N88S in PR were more frequently seen in patients infected 
with subtype AE HIV-1 than in patients infected with subtype B HIV-1. Mutations of D30N, A71V, and 
N88D in PR were often found in patients with subtype B HIV-1. Most of the characteristic mutation 
patterns in that study were associated with a history of treatment with nelfinavir (NFV, Figure 5.1). D30N 
and N88S are particularly related to resistance against NFV.82,99,104,105 The previous chapters suggest the 
resistant mechanism due to each mutation. However, it has not been understood why N88S emerges more 
predominantly than D30N in patients with subtype AE HIV-1 or why D30N emerges more predominantly 
than N88S in patients with subtype B HIV-1. Subtype AE HIV-1 PR has natural polymorphisms, K20R, 
E35D, M36I, R41K, H69K, L89M, and I93L, unlike subtype B PR. These polymorphisms are located at 
non-active site of PR. It is still uncertain whether or not the polymorphisms influence the emergence rates 
of those mutations. To clarify the reason for the difference between the two subtypes in the emergence 
rate of D30N as well as that of N88S, we perform computational simulations of complex of some HIV-1 
PRs and NFV. 
 
 
Figure 5.1. (a) X-ray crystal structure of HIV-1 PR in complex with NFV.94 The PR has two identical 
polypeptide chains, each of which consists of 99 residues P1-F99 and P1’-F99’. Locations of the two 
catalytic aspartates D25/D25’, the 30th and the 88th residues, are shown in ball and stick representation. 
Locations of polymorphisms in subtype AE PR (K20R, E35D, M36I, R41K, H69K, L89M, and I93L) are 
shown in stick representation. Each structure is drawn by the PyMOL ver. 0.99.rc6.87 (b) Hydrogen bond 
network between PR and NFV in the crystal structure.94 (c) Chemical structure of NFV. (d) The amino 
acid sequences of the subtype B wild-type (WT) HIV-1 PR (HXB2) and the reference sequence of 
subtype AE HIV-1 PR (NH1). The polymorphisms in subtype AE PR are highlighted in red letters. 
 - 59 -
Materials and Methods 
Molecular Dynamics (MD) Simulations. Minimizations and MD simulations are carried out in the same 
manner as that described in the chapter 4. In this chapter, we examine the structure of each of the six PRs 
in complex with NFV: the wild-type (WT) PR, D30N PR, and N88S PR of subtype B HIV-1 (labeled 
PR(B:WT)NFV, PR(B:D30N)NFV, and PR(B:N88S)NFV, respectively); the reference (Ref) PR, D30N PR, 
N88S PR of subtype AE HIV-1 in complex with NFV (PR(AE:Ref)NFV, PR(AE:D30N)NFV, and 
PR(AE:N88S)NFV). We use HXB2 as the WT sequence of subtype B HIV-1 and use NH1 as the reference 
sequence of subtype AE HIV-1.137 In the present calculations, the MD simulations show no large 
fluctuations after about 2.0 ns of equilibrating calculations (Figure 5.2 and 5.3). Hence, atom coordinates 
are collected at an interval of 1.0 ps between the 2.0-3.0 ns to analyze the structure in detail. 
 
 
Figure 5.2. RMSD plot during MD simulations about each PR. RMSD were calculated from the 
coordinates of main chain atoms N, C?, C. The residues at codon 8, 23-32, 47-50, 81-84 were selected as 
the active site residues. Each ASP and ASH denotes un-protonated and protonated aspartates. The last 1.0 
ns is highlighted with a yellow background. 
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Figure 5.3. Principal component analyses (PCA) of the whole trajectory during 3.0 ns MD simulation. 
Red and green dots correspond to 0.0-2.0 ns, and 2.0-3.0 ns trajectories. Judging from the 2.0-3.0 ns 
trajectory, the PR-NFV complexes were regarded to be in the equilibrium state. 
 
Next, the protonation states of the catalytic aspartates D25 and D25’ are determined in the 
same manner as that described in the chapter 4. PR(B:D30N)NFV and PR(AE:D30N)NFV are found to prefer 
the combination of protonated D25 and un-protonated D25’. The other four PRs (PR(B:WT)NFV, 
PR(B:N88S)NFV, PR(AE:Ref)NFV, and PR(AE:N88S)NFV) prefers the combination of un-protonated D25 
and protonated D25’ (Table 5.1). 
 
Table 5.1. Determination of the protonation states of D25/D25’ in each PR complexed with NFV. 
Subtype B WT D30N N88S 
ASH25/ASP25’ * 1964.9±40.4 1957.2±42.1 1972.6±37.9 
ASP25/ASH25’ 1957.6±42.3†,‡ 1967.5±39.8 1966.5±40.5 
 
Subtype AE Ref D30N N88S 
ASH25/ASP25’ 1936.7±38.1 1942.7±39.5 1953.1±39.6 
ASP25/ASH25’ 1922.9±39.6 1944.0±39.6 1951.5±38.4 
Energy is presented in units of kcal/mol. 
* Each ASP and ASH denotes un-protonated and protonated aspartates. 
† Bold representation shows the energetically lower model between two. The energetically lower model 
was analyzed in this chapter. 
‡ See also Table 4.1 in the chapter 4. 
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Hydrogen Bond Criteria. The formation of a hydrogen bond is defined in terms of distance and 
orientation, as described in the chapter 2. 
Binding Free Energy Calculation. The binding free energy in solution is calculated with the MM_PBSA 
method in the same manner as that described in the chapter 4. The contribution of each residue to the 
binding energy is also calculated with the MM_GBSA method, as shown in the chapter 4. 
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Results 
Hydrogen Bonds between NFV and PR. First, we examined the hydrogen bonds between NFV and the 
30th residue of PR in each complex: PR(B:WT)NFV, PR(B:D30N)NFV, PR(B:N88S)NFV, PR(AE:Ref)NFV, 
PR(AE:D30N)NFV, and PR(AE:N88S)NFV. We identified direct or one-water-molecule-mediated hydrogen 
bonds from 1000 snapshot structures for the last 1.0 ns (Table 5.2 and 5.3). All six PRs create similar 
hydrogen bond networks. The side chains of both D25 and D25’ interact with the central hydroxyl group 
of NFV (the atom corresponding to O3 in Figure 5.1.c). One water molecule mediates the interaction 
between the main chains of I50/I50’ and NFV. Furthermore, another water molecule mediates the 
interaction between D29’ and NFV. However, the interaction between NFV and the 30th residue has 
variations among the six PRs. In PR(B:WT)NFV and PR(AE:Ref)NFV, either the main chain or the side 
chain of D30 makes direct hydrogen bonds with NFV. D30N and N88S models show different 
interactions between subtype B and AE PRs. PR(B:D30N)NFV has no hydrogen bond between N30 and 
NFV, whereas PR(AE:D30N)NFV has direct or one-water-molecule-mediated hydrogen bonds. 
PR(B:N88S)NFV frequently creates direct hydrogen bond between the main chain of D30 and NFV. On the 
other hand, PR(AE:N88S)NFV mainly creates one-water-molecule-mediated hydrogen bonds between the 
main chain of D30 and NFV. Interestingly, the side chain of N30 in PR(AE:D30N)NFV is clearly closer to 
the m-phenol group of NFV than that of PR(B:D30N)NFV (Figure 5.4). In contrast, the side chain of D30 
in PR(AE:N88S)NFV is more distant from the m-phenol group of NFV than that of PR(B:N88S)NFV. 
 
Table 5.2. Hydrogen bond networks between NFV and PR residues other than D30 or N30 in each 
model. 
(a) D25/D25’ 
Subtype B Subtype AE 
Donor Acceptor % * Donor Acceptor % 
B:WT AE:Ref 
O3† NFV OD1 D25 82.8 O3 NFV OD1 D25 96.1 
O3 NFV OD2 D25 99.8 O3 NFV OD2 D25 98.5 
OD2 D25’ O3 NFV 100.0 OD2 D25’ O3 NFV 100.0 
B:D30N AE:D30N 
O3 NFV OD2 D25’ 99.3 O3 NFV OD2 D25’ 100.0 
OD2 D25 O3 NFV 61.2 OD2 D25 O3 NFV 72.8 
B:N88S AE:N88S 
O3 NFV OD1 D25 98.9 O3 NFV OD1 D25 70.9 
O3 NFV OD2 D25 98.1 O3 NFV OD2 D25 99.1 
OD2 D25’ O3 NFV 100.0 OD2 D25’ O3 NFV 100.0 
(continued to the next page) 
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Tabel 5.2. (continued) 
(b) I50/I50’ 
Subtype B Subtype AE 
Donor Acceptor %  Donor Acceptor % 
B:WT AE:Ref 
O WAT207 O2 NFV 98.5 O WAT209 O2 NFV 98.5 
O WAT207 O4 NFV 90.5 O WAT209 O4 NFV 92.6 
N I50 O WAT207 94.7 N I50 O WAT209 81.5 
N I50’ O WAT207 97.7 N I50’ O WAT209 97.2 
B:D30N AE:D30N 
O WAT209 O2 NFV 95.8 O WAT211 O2 NFV 93.8 
O WAT209 O4 NFV 66.1 O WAT211 O4 NFV 92.5 
N I50 O WAT209 84.6 N I50 O WAT211 85.3 
N I50’ O WAT209 96.8 N I50’ O WAT211 96.5 
B:N88S AE:N88S 
O WAT205 O2 NFV 96.7 O WAT209 O2 NFV 91.2 
O WAT205 O4 NFV 86.2 O WAT209 O4 NFV 95.4 
N I50 O WAT205 88.7 N I50 O WAT209 76.8 
N I50’ O WAT205 96.2 N I50’ O WAT209 97.2 
(c) D29’ 
Subtype B Subtype AE 
Donor Acceptor %  Donor Acceptor % 
 B:WT AE:Ref 
N3 NFV O WAT4033 25.9 N3 NFV O WAT4056 29.8 
N D29’ O WAT4033 23.5 N D29’ O WAT4056 27.2 
O WAT4033 OD1/OD2 D29’ 25.3 O WAT4056 OD1 D29’ 21.9 
N3 NFV O WAT6585 47.6 N3 NFV O WAT4716 12.6 
N D29’ O WAT6585 44.8 N D29’ O WAT4716 11.6 
O WAT6585 OD1/OD2 D29’ 36.9 O WAT4716 OD1 D29’ 5.5 
N3 NFV O WAT7627 18.8 N3 NFV O WAT6480 16.7 
N D29’ O WAT7627 17.6 N D29’ O WAT6480 14.9 
O WAT7627 OD2 D29’ 5.5 O WAT6480 OD1 D29’ 14.8 
B:D30N AE:D30N 
N3 NFV O WAT6055 85.7 N3 NFV O WAT1749 19.8 
N D29’ O WAT6055 76.8 N D29’ O WAT1749 19.6 
O WAT6055 OD1/OD2 D29’ 78.4 N3 NFV O WAT4596 21.0 
     N D29’ O WAT4596 20.9 
     O WAT4596 OD1 D29’ 6.0 
     N3 NFV O WAT4776 29.1 
     N D29’ O WAT4776 29.1 
     N3 NFV O WAT6606 16.1 
     N D29’ O WAT6606 16.1 
 B:N88S AE:N88S 
N3 NFV O WAT2312 91.0 N3 NFV O WAT4441 61.8 
N D29’ O WAT2312 83.7 N D29’ O WAT4441 54.1 
O WAT2312 OD1/OD2 D29’ 78.0 O WAT4441 OD1/OD2 D29’ 59.0 
     N3 NFV O WAT6151 26.2 
     N D29’ O WAT6151 22.9 
     O WAT6151 OD1/OD2 D29’ 22.9 
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
† The atom names of NFV are shown in Figure 5.1.c. 
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Table 5.3. Hydrogen bond networks of NFV with D30 or N30 in PR. 
Subtype B Subtype AE 
Donor Acceptor %* Donor Acceptor % 
B:WT AE:Ref 
N D30 O1† NFV 30.7 N D30 O1 NFV 5.7 
O1 NFV OD1/OD2 D30 31.6 O1 NFV OD1/OD2 D30 69.2 
O1 NFV O D30 42.9 O1 NFV O D30 9.0 
B:D30N AE:D30N 
     O1 NFV OD1 N30 25.2 
     O1 NFV O WAT766 12.6 
     O WAT766 OD1 N30 12.1 
     O1 NFV O WAT1770 8.4 
     O WAT1770 OD1 N30 6.8 
     O1 NFV O WAT8063 13.7 
     O WAT8063 OD1 N30 9.1 
B:N88S AE:N88S 
N D30 O1 NFV 26.7 N D30 O1 NFV 7.4 
O1 NFV OD2 D30 12.4      
O1 NFV O D30 56.7 O1 NFV O D30 27.9 
     O1 NFV O WAT6715 28.8 
     N D30 O WAT6715 28.3 
     O WAT6715 N D30 12.6 
     O WAT6715 O D30 31.8 
     O1 NFV O WAT7886 13.6 
     O WAT7886 OD1 D30 5.2 
     O WAT7886 O D30 25.5 
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
† The atom names of NFV are shown in Figure 5.1.c. 
 
Figure 5.4. Distance between NFV and the 30th residue. Each red and green solid line corresponds to the 
distance between N of the 30th residue and the O1 atom of NFV and to the distance between O of the 
30th residue and the O1 atom of NFV. Blue solid lines of PR(B:WT)NFV, PR(AE:Ref)NFV, PR(B:N88S)NFV, 
and PR(AE:N88S)NFV show the distances between O1 of NFV and OD1/OD2 of D30, while those of 
PR(B:D30N)NFV and PR(AE:D30N)NFV show the distances between O1 of NFV and OD1/ND2 of N30. 
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Comparison of the Structures with PR(B:WT)NFV. To clarify the effects of mutations at the 30th and 
the 88th residues on active site conformations of PR, the average structure of each model for the last 1.0 
ns was compared with that of PR(B:WT)NFV. Each model was fitted to PR(B:WT)NFV using the 
coordinates of main chain atoms N, C?, and C, and the root mean squared deviation (RMSD) value was 
calculated (Figure 5.5). When active site residues of each PR are compared with those of PR(B:WT)NFV, 
conformational changes are observed only on the active site residues around the 30th residue. When each 
subtype B PR is compared with the corresponding subtype AE PR, PR(B:D30N)NFV is found to have 
larger conformational changes on N30 than PR(AE:D30N)NFV. PR(AE:N88S)NFV shows larger 
conformational changes on D30 than PR(B:N88S)NFV. Next, we compared the location of NFV in each 
model with that of PR(B:WT)NFV. The m-phenol group of NFV, which interacts with the 30th residue, 
shows a larger positional deviation than the other parts of NFV in every model (Figure 5.7). 
 
 
Figure 5.5. 3D plot of RMSD of the average structure of each model from that of PR(B:WT)NFV. The PR 
in each model is shown in colored tube representation. The color refers to the magnitude of RMSD shown 
in the right bar. In each PR the left chain consists of P1-F99, and the right chain consists of P1’-F99’. 
Each model was fitted to PR(B:WT)NFV using the coordinates of main chain atoms N, C?, and C of PR. 
The superimposed gray tubes represent the structure of PR(B:WT)NFV. Each structure is drawn by the 
PyMOL ver. 0.99.rc6.87 
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Figure 5.6. The RMSD value on the 30th residue of the average structure of each PR from that of 
PR(B:WT)NFV. Error bars show root-mean-squared fluctuations (RMSF). 
 
 
 
Figure 5.7. 3D plot of RMSD of the average structure from that of PR(B:WT)NFV. Ligand in each model 
is shown in colored tube representation. The color means the magnitude of RMSD shown in the right bar. 
Each model was fitted on PR(B:WT)NFV using the coordinates of main chain atoms N, C? and C of PR. 
The superimposed gray sticks represent the structure of PR(B:WT)NFV. Each structure is drawn by the 
PyMOL ver. 0.99.rc6.87 
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Table 5.4. Binding free energy of each model. 
  ?G int
ele  ?G int
vdW  ?G sol
  ?G b
  * ??G b
 † ??G b
 ‡ 
WT (B) -12.5±1.4 -71.8±3.8 15.1±1.4 -69.2±3.7 - - 
Ref (AE) -12.8±1.7 -70.8±4.0 15.1±1.5 -68.6±3.7 - - 
D30N (B) -6.9±1.2 -70.5±4.1 10.9±0.9 -66.5±3.9 2.7 - 
 (AE) -7.5±1.3 -70.2±3.9 9.5±1.0 -68.2±3.7 - 0.4 
N88S (B) -12.0±1.3 -71.7±3.8 15.0±1.2 -68.7±3.7 0.5 - 
 (AE) -10.6±1.4 -67.8±4.0 12.8±1.9 -65.6±3.9 - 3.0 
Energy is presented in units of kcal/mol. 
* ?T?S 
  is not included. 
† Difference from PR(B:WT)NFV. 
‡ Difference from PR(AE:Ref)NFV. 
 
Binding Free Energy Calculations. The influence of the mutations on the binding free energy ?Gb was 
examined for each model. Table 5.4 shows the results of MM_PBSA calculations for all of PRs in 
complex with NFV. In subtype B HIV-1, PR(B:D30N)NFV reduces the binding energy with NFV from 
PR(B:WT)NFV more than PR(B:N88S)NFV does. On the other hand, in subtype AE HIV-1, 
PR(AE:D30N)NFV shows affinity with NFV similar to PR(AE:Ref)NFV, and has higher affinity with NFV 
than PR(AE:N88S)NFV. The results correspond to the emergence rates of subtypes B and AE variants in 
patients for whom treatment with NFV has failed. D30N predominantly emerges in patients with subtype 
B HIV-1, whereas N88S predominantly emerges in patients with subtype AE HIV-1. We also 
investigated the contributions of the respective residues to the binding free energy (Figure 5.8). In all six 
models, the active site residues stabilize the complex of each PR and NFV. When we focus on the binding 
energy due to the 30th residue, D30 or N30, PR(B:D30N)NFV reduces the contribution to the binding free 
energy in comparison with PR(B:WT)NFV (Figure 5.9). PR(AE:N88S)NFV also reduces the contribution to 
the binding energy compared with PR(AE:Ref)NFV. PR(B:N88S)NFV shows contribution similar to that of 
PR(B:WT)NFV, and PR(AE:D30N)NFV shows a contribution similar to that of PR(AE:Ref)NFV. 
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Figure 5.8. (a) Contribution of the individual residues to binding free energy. (b) Difference in 
contribution of the individual residues to the binding energy between each model and PR(B:WT)NFV. The 
energetic contributions of the residues are shown in red solid lines, and those of PR(B:WT)NFV in green 
lines. The bottom black lines indicate the locations of the active site residues (R8, L23-V32, I47-I50, 
P81-I84, R8’, L23’-V32’, I47’-I50’, P81’-I84’). 
 
 
Figure 5.9. Contribution of the 30th residue to binding free energy in each model. Error bars stand for 
standard deviation. 
 - 69 -
Discussion 
In this chapter, we performed MD simulations of HIV-1 PRs in complex with NFV for the 
purpose of clarifying the reason why the emergence rates of D30N and N88S differ between subtypes B 
and AE HIV-1. 
Ariyoshi et al. reported that D30N emerged predominantly in patients with subtype B HIV-1 
whereas N88S appeared predominantly in patients with subtype AE HIV-1.46 Subtype AE HIV-1 PR has 
some natural polymorphisms (K20R, E35D, M36I, R41K, H69K, L89M, and I93L) unlike subtype B PR. 
These amino acids are located at non-active sites of PR. To reveal what causes the difference in the 
emergence rates of D30N and N88S, we carried out simulations of some complexes of PRs with NFV: 
PR(B:WT)NFV, PR(B:D30N)NFV, PR(B:N88S)NFV PR(AE:Ref)NFV, PR(AE:D30N)NFV, and 
PR(AE:N88S)NFV. The results suggest that D30N and N88S mutations show different effects between 
subtypes B and AE PRs. D30N in subtype B PR greatly reduces the binding affinity with NFV because 
the hydrogen bonds between N30 and NFV are canceled, as we have shown in the chapter 2. In contrast, 
D30N in subtype AE PR hardly affects the affinity with NFV. PR(AE:D30N)NFV has direct or 
one-water-molecule-mediated hydrogen bonds between N30 and NFV. On the other hand, N88S in 
subtype AE PR significantly reduces the binding affinity with NFV, whereas N88S in subtype B PR 
hardly affects the affinity with NFV. In both PR(B:N88S)NFV and PR(AE:N88S)NFV, a hydrogen bond is 
created between the side chain of D30 and the side chain of S88 (Table 5.5). However, the interactions of 
NFV with D30 differ between subtype B and AE PRs. PR(B:N88S)NFV has direct hydrogen bond between 
the main chain of D30 and NFV, whereas PR(AE:N88S)NFV mainly has one-water-molecule-mediated 
hydrogen bonds between the main chain of D30 and NFV. D30N PR has lower affinity with NFV than 
does N88S PR in subtype B HIV-1. In contrast, D30N PR has higher affinity than N88S PR in subtype 
AE HIV-1. These results are compatible with the results of a study by Ariyoshi et al.46 Both D30N and 
N88S mutations in HIV-1 PRs exhibit significant losses of viral fitness.99,105 Therefore, D30N and N88S 
mutants of HIV-1 have low growth kinetics relative to WT or Ref variants under the condition without 
any PIs. Nevertheless, it is frequently observed that D30N mutant emerges in patients with subtype B 
HIV-1 for whom treatment with NFV has failed and that N88S mutant emerges in the patients with 
subtype AE HIV-1.46 These results indicate that the effectiveness of NFV is significantly reduced for 
these mutants. In contrast, N88S mutants of subtype B PR and D30N mutants of subtype AE PR have 
rarely been seen clinically. This is considered to be due not only to their low degree of fitness but also to 
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their affinities with NFV comparable to those of subtype B WT or subtype AE Ref variants. Our 
simulations suggest that the natural polymorphisms of subtype AE PR, in spite of the non-active site 
mutations, reduce the emergence rate of D30N and increase that of N88S.  
 
Table 5.5. Hydrogen bond networks of the side chain of D30 or N30 with PR residues. 
Subtype B Subtype AE 
Donor Acceptor %* Donor Acceptor % 
B:WT AE:Ref 
NZ K45 OD1/OD2 D30 67.0 NZ K45 OD1 D30 38.3 
B:D30N AE:D30N 
ND2 N30 O T74 89.7      
ND2 N30 N T31 59.5      
ND2 N30 O T31 98.1      
N T31 ND2 N30 67.9      
     ND2 N30 O WAT224 76.9 
     N T31 O WAT224 72.6 
     O WAT224 O T31 70.7 
     O WAT224 O T74 76.8 
     ND2 N88 O WAT224 39.4 
B:N88S AE:N88S 
OG S88 OD1 D30 34.7 OG S88 OD2 D30 77.8 
O WAT1142 OD1/OD2 D30 46.2 O WAT226 OD2 D30 33.7 
N T31 O WAT1142 38.3 OG1 T31 O WAT226 18.1 
     N T31 O WAT226 31.4 
O WAT1142 O T74 45.1 O WAT226 O T74 33.8 
OG S88 O WAT1142 40.9      
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
 
The polymorphisms in subtype AE PR increase the emergence rate of N88S. However, there 
remains the question of which is the key mutation that influences the emergence rate of N88S among the 
polymorphisms K20R, E35D, M36I, R41K, H69K, L89M, and I93L. We focused on M36I for three 
reasons. First, M36I is related to the resistance against NFV.13 Second, N88S has been observed in 
combination with mutations at various positions, including 20, 36, 46, 63, and 77.104 Third, M36I is 
frequently observed as a polymorphism in other subtypes, namely, A and C.144,145 We executed the 
additional simulations of M36I PR, M36I/N88S PR, and L10F/M36I/N88S PR of subtype B HIV-1 in 
complex with NFV (labeled PR(B:M36I)NFV, PR(B:M36I/N88S)NFV, and PR(B:L10F/M36I/N88S)NFV, 
respectively) (Figure 5.10 and Table 5.6). L10F is a mutation that is frequently seen in subtype AE HIV-1 
accompanied by N88S.46 Our simulations suggest that the single M36I mutation in subtype B PR does not 
influence NFV binding. PR(B:M36I)NFV has stable hydrogen bonds between NFV and D30 (Table 5.7 and 
Figure 5.11). In contrast, the combination of the M36I and N88S mutations in subtype B PR reduces the 
binding affinity with NFV. PR(B:M36I/N88S)NFV has fewer hydrogen bonds with NFV than 
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PR(B:M36I)NFV or PR(B:N88S)NFV does. Furthermore, the conformational change at D30 is larger in 
PR(B:M36I/N88S)NFV than in PR(B:M36I)NFV or PR(B:N88S)NFV (Figure 5.12 and 5.13). 
PR(B:L10F/M36I/N88S)NFV also creates fewer hydrogen bonds between NFV and D30 and causes 
conformational alteration at D30. The polymorphism M36I reduces the contribution of D30 to the binding 
with NFV (Figure 5.14). Our simulations suggest that N88S in subtype B PR reduces the binding affinity 
with NFV when it appears together with M36I.  
 
 
Figure 5.10. (a) RMSD plot during MD simulations about each PR. See also Figure 5.2. (b) Principal 
component analyses (PCA) of the whole trajectory during 3.0 ns MD simulation. See also Figure 5.3. 
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Table 5.6. Determination of the protonation states of D25/D25’ in each PR complexed with NFV. 
(a) Comparison of free energies between two protonation states (See also Table 5.1). 
Subtype B M36I M36I/N88S L10F/M36I/N88S 
ASH25/ASP25’* 1972.9±39.3 1978.3±40.2 * 1981.2±39.2 
ASP25/ASH25’ 1990.2±41.7 1978.3±40.6 * 1990.6±41.1 
Energy is presented in units of kcal/mol. 
*  The two free energies were equal. Hence, both protonation states of PR(B:M36I/N88S)NFV were 
employed in the binding energy comparison. 
(b) Binding energy of each subtype B PR model (See also Table 5.4). 
  ?G int
ele  ?G int
vdW  ?G sol
  ?G b
   ??G b
 *  
M36I (B) -11.8±1.2 -73.3±3.7 15.4±1.1 -69.7±3.5 -0.5 
M36I/N88S (B)ASH25/ASP25’ -8.2±1.5 -65.7±3.4 11.9±1.5 -61.9±3.5 7.3 
 (B)ASP25/ASH25’ -11.0±0.9 -70.8±3.4 14.6±1.4 -67.2±3.3c 2.0 
L10F/M36I/N88S (B) -8.3±1.2 -71.2±3.9 12.9±1.6 -66.5±3.9 2.7 
Energy is presented in units of kcal/mol. 
*  Difference from PR(B:WT)NFV. 
† When we compared binding energies of PR(B:M36I/N88S)NFV between two protonation states, the 
ASP25/ASH25’ protonation state has larger binding affinity with NFV. Thus, we used the 
ASP25/ASH25’ protonation state model to analyze hydrogen bonds and conformational changes. 
 
 
Table 5.7. Hydrogen bond networks of D30 in PR(B:M36I)NFV, PR(B:M36I/N88S)NFV, and 
PR(B:L10F/M36I/N88S)NFV. 
(a) NFV-D30 (b) D30-the other PR residues 
Donor Acceptor %* Donor Acceptor % 
B:M36I) 
O1 NFV OD2 D30 95.3 NZ K45 OD1/OD2 D30 84.5 
B:M36I/N88S) 
O1 NFV O D30 27.7 OG  S88 OD1 D30 91.4 
B:L10F/M36I/N88S) 
O1 NFV O WAT3541 37.4 OG  S88 OD1 D30 99.0 
O D30 O WAT3541 33.7      
O WAT3541 O D30 37.7      
O1 NFV O WAT4238 26.7      
O D30 O WAT4238 23.3      
O WAT4238 O D30 24.3      
* Occupancy of hydrogen bonds during 2.0-3.0 ns MD simulation. 
† The atom names of NFV are shown in Figure 5.1.c. 
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Figure 5.11. Distance between NFV and D30 in PR(B:M36I)NFV, PR(B:M36I/N88S)NFV, and 
PR(B:L10F/M36I/N88S)NFV. Each of the red and green solid lines corresponds to the distance between N 
of D30 and O1 atom of NFV and the distance between O of the 30th residue and O1 atom of NFV. Blue 
solid lines show the distances between O1 of NFV and OD1/OD2 of D30. 
 
 
Figure 5.12. 3D plot of RMSD of the average structure of PR(B:M36I)NFV, PR(B:M36I/N88S)NFV, and 
PR(B:L10F/M36I/N88S)NFV from that of PR(B:WT)NFV. PR in each model is shown in colored tube 
representation. The color means the magnitude of RMSD shown in the right bar. In each PR, the left 
chain consists of P1-F99, and the right chain consists of P1’-F99’. Each model was fitted on 
PR(B:WT)NFV using the coordinates of main chain atoms N, C? and C of PR. The superimposed gray 
sticks and tubes represent the structure of PR(B:WT)NFV. Each structure is drawn by the PyMOL ver. 
0.99.rc6.87 
 
 
Figure 5.13. RMSD value of D30 in the average structure of each PR from that of PR(B:WT)NFV. Error 
bars show root mean squared fluctuations (RMSF). 
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Figure 5.14. Contribution of the 30th residue to binding energy in each model. Error bars show standard 
deviations. 
 
It is interesting that both D30N and N88S confer resistance against NFV by decreasing the 
interaction between the 30th residue and NFV. Both D30N and N88S influence the active site residues 
around the 30th residue. Other active site residues hardly change their interaction with NFV or their 
conformations. As can be seen in Figure 5.4 and Figure 5.11, all the NFV-resistant PRs (PR(B:D30N)NFV, 
PR(AE:N88S)NFV, PR(B:M36I/N88S)NFV, and PR(B:L10F/M36I/N88S)NFV) show an increase in distance 
between the 30th residue and NFV. Every NFV-resistant N88S mutant (PR(B:N88S)NFV, 
PR(AE:N88S)NFV, PR(B:M36I/N88S)NFV, and PR(B:L10F/M36I/N88S)NFV) have stable direct hydrogen 
bond between the side chain of S88 and the side chain of D30 (Table 5.6). Therefore, N88S does not 
appear simultaneously with D30N clinically. 
In this chapter, we examined the influence of the polymorphisms in subtype AE PR on the 
emergence rates of D30N and N88S mutations. It has been reported that polymorphisms in non-subtype B 
HIV-1 influence the binding affinity of some inhibitors, the emergence rate of mutations, and the catalytic 
activity of PR.65,72,74,97,137,146-148 For example, the polymorphisms in subtype C HIV-1 enhance the catalytic 
efficacy. However, there have been few studies on the differences between HIV-1 subtypes from a 
structural viewpoint. Accumulation of data on the structural differences is needed in order to combat the 
diversity of HIV. 
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Chapter 6 
Structural Role of M36I in HIV-1 PR 
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Introduction 
Non-active site mutation M36I is commonly observed polymorphism in non-subtype B 
HIV-1 proteases (HIV-1 PRs). 50,149,150 Furthermore, M36I is known to be associated with resistance 
against some FDA-approved PIs: nelfinavir (NFV, Figure 6.1), indinavir, ritonavir, and atazanavir.13 
Therefore, M36I is a key mutation to understand the difference between subtype B and non-subtype B 
HIV-1 PRs. For example, M36I enhances the emergence rate of N88S in CRF01_AE HIV-1 PR, as 
shown in the previous chapter. In this chapter, we investigate the structural role of M36I in the binding of 
PR with NFV in more detail. 
 In addition to the role of the single mutation M36I, we investigate the relationship between 
D30N and the mutation at the 36th residue of PR. It is known that D30N hardly emerges in non-subtype 
B HIV-1 PR.26,27,50 We discuss the rare emergence of D30N in non-subtype B viruses from a structural 
viewpoint. 
 
 
 
Figure 6.1. (a) X-ray crystal structure of HIV-1 PR in complex with NFV.94 The PR has two identical 
polypeptides, each of which consists of 99 residues P1-F99 and P1’-F99’. Locations of the two catalytic 
aspartate residues D25/D25’, the 30th and the 36th residues, and NFV are shown in ball and stick 
representations. Each structure is drawn by the PyMOL ver. 0.99.rc6.87 (b) Hydrogen bond network 
between PR and NFV in the crystal structure.94 (c) Chemical structure of NFV. (d) The amino acid 
sequence of the subtype B wild-type (WT) HIV-1 PR (HXB2) and that of M36I mutant. 
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Materials and Methods 
Molecular Dynamics (MD) Simulation. We perform minimizations and MD simulations in the same 
manner as that described in the chapter 4. We investigate six proteases in complex with NFV: the 
wild-type (WT) PR, M36I PR, M36V PR, D30N PR, D30N/M36I PR, and D30N/M36V PR of subtype B 
HIV-1 (labeled as PR(B:WT)NFV, PR(B:M36I)NFV, PR(B:M36V)NFV, PR(B:D30N)NFV, 
PR(B:D30N/M36I)NFV, and PR(B:D30N/M36V)NFV, respectively). PR(B:M36V)NFV and 
PR(B:D30N/M36V)NFV are also examined in order to analyze the effect of the side-chain of the 36th 
residue clearly. We use HXB2 as the WT sequence of subtype B HIV-1. In the present calculations, the 
MD simulations showed no large fluctuations after about 2.0 ns equilibrating calculation (Fig. 6.2 and 
6.3). Hence, atom coordinates are collected at an interval of 1.0 ps for the last 1.0 ns to analyze the 
structure in detail.  
 
 
Figure 6.2. RMSD plots during the 3.0 MD simulations about each PR. RMSD were calculated from 
coordinates of main chain atoms N, C?, C. The residues at codon 8, 23-32, 47-50, 81-84 were selected as 
the active site residues. Each ASP and ASH denotes un-protonated and protonated aspartic acids. The last 
1.0 ns are highlighted with a yellow background. 
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Figure 6.3. Principal component analyses (PCA) of whole trajectories during the 3.0 ns MD simulations. 
Red and green dots correspond to the 0.0-2.0 ns, and the 2.0-3.0 ns trajectories. 
 
Next, the protonation states of the catalytic aspartic acids D25 and D25’ are determined in the 
same method as that described in the chapter 4. PR(B:D30N)NFV, PR(B:M36I)NFV, and 
PR(B:D30N/M36I)NFV have been found to favor the combination of protonated D25 and un-protonated 
D25’ (Table 6.1). The other three PRs, PR(B:WT)NFV, PR(B:M36V)NFV and PR(B:D30N/M36V)NFV, 
prefer the combination of un-protonated D25 and protonated D25’. 
 
Table 6.1. Determination of the protonation states of D25/D25’ of each PR in complex with NFV. 
Subtype B WT M36I M36V 
ASH25/ASP25’ * 1964.9±40.4 1972.9±39.3 1966.5±40.0 
ASP25/ASH25’ 1957.6±42.3 †,‡ 1990.2±41.7 1951.1±38.9 
 
Subtype B D30N D30N/M36I D30N/M36V 
ASH25/ASP25’ * 1957.2±42.1 1982.2±41.1 1989.3±39.3 
ASP25/ASH25’ 1967.5±39.8 1983.9±40.3 1983.2±41.2 
Energy is presented in units of kcal/mol. 
* Each ASP and ASH denotes un-protonated and protonated aspartic acids. 
† Bold representation shows the model giving lower energy between two. The model giving lower energy 
was analyzed in this chapter. 
‡ See also Table 4.1 in the chapter 4. 
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Hydrogen Bond Criteria. The formation of a hydrogen bond is defined in terms of distance and 
orientation, as described in the chapter 2. 
Calculations of Volume and Surface Area of the Binding Cavity. We employ the Pocket program151 to 
estimate the volume and the surface area of a ligand-binding cavity of PR. The program is based on the 
Alpha Shape theory,151 which provides an analytical method for detecting pockets in proteins and 
measuring their volume and surface area. The ligand-binding cavity of HIV-1 PR is not completely 
separated from solvent. However, it should be noted that, in the Pocket program, a pocket is defined as a 
cavity that is inaccessible to the solvent outside of a protein. If a water molecule is trapped within the 
pocket, the water molecule cannot escape to the outside of the protein. Hence, we can define the 
ligand-binding cavity as a pocket. Figure 6.4 shows the binding pocket of HIV-1 PR visualized by the 
MAGE program.152 
 
 
Figure 6.4. Ligand-binding pocket of HIV-1 PR. (a) CPK model of the atoms bordering the pocket. The 
radii of the balls are set to the van der Waals radii of the respective atoms. (b) Line representation of the 
binding pocket. The pocket is divided into many tetrahedral segments. The vertices of the triangles 
forming each of the tetrahedron correspond to the atoms of the protein those border the pocket. The 
volume of the pocket is defined as a sum of the volume of these tetrahedra. 
 
Binding Free Energy Calculation. The binding free energy in solution is calculated with the MM_PBSA 
method in the same manner as that described in the chapter 4. The contribution of each residue to the 
binding energy is also calculated with the MM_GBSA method, as shown in the chapter 4. 
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Results 
Hydrogen Bond Networks. We performed MD simulations of six subtype B HIV-1 PRs in complex with 
NFV: PR(B:WT)NFV, PR(B:M36I)NFV, PR(B:M36V)NFV, PR(B:D30N)NFV, PR(B:D30N/M36I)NFV, and 
PR(B:D30N/M36V)NFV. First, in order to clarify the structural role of mutation at the 36th residue, we 
examined direct or one-water-molecule-mediated hydrogen bonds between each PR and NFV (Table 6.2). 
According to the X-ray crystal structure of HIV-1 PR bound to NFV,94 NFV has direct and 
one-water-molecule-mediated hydrogen bonds with D25/D25’, I50/I50’, D29’, and D30 (Figure 6.1.b). In 
all of the six models, the side-chains of D25 and D25’ directly interact with the central hydroxyl group of 
NFV (O3 in Figure 6.1.c). All of models also have one-water-molecule-mediated hydrogen bonds of NFV 
with I50/I50’ and with D29’. Different hydrogen bonds are observed between the 30th residue and the 
phenol group of NFV. In PR(B:WT)NFV and PR(B:M36V)NFV, either the main chain or the side-chain of 
D30 interacts with NFV through hydrogen bonds (Figure 6.5). In PR(B:M36I)NFV, only the side-chain of 
D30 forms a hydrogen bond with NFV. In contrast, PR(B:D30N)NFV has no hydrogen bond with NFV. 
PR(B:D30N/M36I)NFV and PR(B:D30N/M36V)NFV show a different feature from that of PR(B:D30N)NFV. 
They have direct hydrogen bonds between the main chain of N30 and NFV. 
 
 
Table 6.3. Hydrogen bond networks of NFV with D25/D25’, I50/I50’, or D29’. 
(a) D25/D25’ 
Donor Acceptor % Donor Acceptor % 
WT D30N 
O3 NFV OD1 D25 82.8 O3 NFV OD2 D25’ 99.3 
O3 NFV OD2 D25 99.8 OD2 D25 O3 NFV 61.2 
OD2 D25’ O3 NFV 100.0      
M36I D30N/M36I 
OD2 D25  NFV 97.1 OD2 D25 O3 NFV 89.4 
O3 NFV  D25’ 100.0 O3 NFV OD2 D25’ 100.0 
M36V D30N/M36V 
OD2 D25’ O3 NFV 100.0 OD2 D25’ O3 NFV 100.0 
O3 NFV OD1 D25 96.6 O3 NFV OD2 D25 98.4 
O3 NFV OD2 D25 97.8      
(continued to the next page) 
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Table 6.2 (continued) 
(b) I50/I50’ 
Donor Acceptor % Donor Acceptor % 
WT D30N 
O WAT207 O2 NFV 98.5 O WAT209 O2 NFV 95.8 
O WAT207 O4 NFV 90.5 O WAT209 O4 NFV 66.1 
N I50 O WAT207 94.7 N I50 O WAT209 84.6 
N I50’ O WAT207 97.7 N I50’ O WAT209 96.8 
M36I D30N/M36I 
O WAT207 O2 NFV 93.8 O WAT209 O2 NFV 93.0 
O WAT207 O4 NFV 91.3 O WAT209 O4 NFV 92.3 
N I50 O WAT207 84.3 N I50 O WAT209 76.4 
N I50’ O WAT207 96.4 N I50’ O WAT209 97.5 
M36V D30N/M36V 
O WAT207 O2 NFV 98.7 O WAT209 O2 NFV 97.9 
O WAT207 O4 NFV 94.7 O WAT209 O4 NFV 92.4 
N I50 O WAT207 83.2 N I50 O WAT209 92.8 
N I50’ O WAT207 97.9 N I50’ O WAT209 98.1 
(c) D29’ 
Donor Acceptor % Donor Acceptor % 
WT D30N 
N3 NFV O WAT4033 25.9 N3 NFV O WAT6055 85.7 
N D29’ O WAT4033 23.5 N D29’ O WAT6055 76.8 
O WAT4033 OD1/OD2 D29’ 25.3 O WAT6055 OD1/OD2 D29’ 78.4 
N3 NFV O WAT6585 47.6      
N D29’ O WAT6585 44.8      
O WAT6585 OD1/OD2 D29’ 36.9      
N3 NFV O WAT7627 18.8      
N D29’ O WAT7627 17.6      
O WAT7627 OD2 D29’ 5.5      
M36I D30N/M36I 
N3 NFV O WAT2631 96.2 N3 NFV O WAT734 94.2 
N D29’ O WAT2631 90.5 N D29’ O WAT734 91.8 
O WAT2631 OD1 D29’ 91.5 O WAT734 OD1 D29’ 39.2 
     O WAT734 OD2 D29’ 33.9 
M36V D30N/M36V 
N3 NFV O WAT4523 42.5 N3 NFV O WAT6805 94.3 
N D29’ O WAT4523 38.0 N D29’ O WAT6805 89.3 
O WAT4523 OD2 D29’ 41.9 O WAT6805 OD2 D29’ 74.5 
N3 NFV O WAT6047 21.3      
N D29’ O WAT6047 18.5      
O WAT6047 OD2 D29’ 19.3      
N3 NFV O WAT6596 15.5      
N D29’ O WAT6596 14.7      
O WAT6596 OD2 D29’ 13.4      
(d) D30 
Donor Acceptor % Donor Acceptor % 
WT D30N 
N D30 O1 NFV 30.7      
O1 NFV OD1/OD2 D30 31.6      
O1 NFV O D30 42.9      
M36I D30N/M36I 
O1 NFV OD2 D30 95.3 O1 NFV O N30 57.1 
M36V D30N/M36V 
N D30 O1 NFV 18.0 N N30 O1 NFV 24.9 
O1 NFV OD1/OD2 D30 46.1      
O1 NFV O D30 35.9 O1 NFV O N30 34.7 
* Occupancy of hydrogen bonds during the 2.0-3.0 ns MD simulation. 
† The atom names of NFV are shown in Figure 6.1.c. 
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Figure 6.5. Distance between the 30th residue of PR and NFV. Red and green solid lines correspond to 
the distance between N of the 30th residue and O1 atom of NFV and that between O of the 30th residue 
and O1 atom of NFV, respectively. Blue solid lines of PR(B:WT)NFV, PR(B:M36I)NFV, and 
PR(B:M36V)NFV show the distance between OD1/OD2 of D30 and O1 atom of NFV, while those of 
PR(B:D30N)NFV, PR(B:D30N/M36I)NFV, and PR(B:D30N/M36V)NFV are the distance between OD1/ND2 
of N30 and O1 atom of NFV. 
 
Change in Conformation of PR. Next, we investigated the difference in the average structure of each 
PR from that of PR(B:WT)NFV. The average structure of each PR was generated from 1000 snapshot 
structures during the last 1.0 ns of MD simulations. In order to make a comparison between each PR and 
PR(B:WT)NFV, we superimposed the average structure of each PR onto that of PR(B:WT)NFV using the 
coordinates of main chain atoms N, C?, and C. Since non-active site residues of PR are more flexible 
than active site residues of PR, and the structure of non-active site residues is largely influenced by 
random atom motions in MD simulation (Figure 6.6), we focused on conformational change of the active 
site residues. Figure 6.7 shows that the displacements of most of the active site residues are small. 
Detailed values are shown in Figure 6.8. Exceptionally, large conformational change (RMSD=1.5 Å) is 
observed at D29 in PR(B:D30N/M36I)NFV. In the other PRs, D29 is shifted about 0.7 Å. D30 is noticeably 
displaced by 0.8 Å in only PR(B:D30N)NFV, while displacement of the 30th residues is less than 0.5 Å in 
the other PRs. At flap region and around 80’s loop of PR, slight conformational changes are also 
observed. The flap and 80’s loop consist of the 47th to 50th residues and of the 79th to 81st residues, 
respectively. Although HIV-1 PR is a homo-dimer, the asymmetric displacements are observed. The 
displacement in NFV was also examined (Figure 6.9). Conformational changes in the m-phenol group and 
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the thio-phenyl group (C6H6-S-) are observed. PR(B:D30N)NFV and PR(B:D30N/M36I)NFV show larger 
displacement than that of the other models. In contrast, the tert-butylcarboxamide moiety and the 
dodecahydroisoquinoline ring hardly change their locations in each model. The displacements of NFV are 
also asymmetric and correlate with the displacements of PR. The residues near the m-phenol group of 
NFV, such as the 29th and 30th residues, show large displacement. On the other hand, the residues near 
the tert-butylcarboxamide moiety or the dodecahydroisoquinoline ring of NFV show small displacements. 
The asymmetric displacements observed in HIV-1 PR will be due to the structural collision with NFV. 
 
 
 
Figure 6.6. B-factors of the individual residues in each model. Red and green lines represent B-factors of 
each model and those of PR(B:WT)NFV, respectively. Blue dots show B-factors of the 36th residues. Black 
dots represent the locations of the active site residues of PR. 
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Figure 6.7. 3D plot of RMSD of the average structure of each model from that of PR(B:WT)NFV. PR is 
shown in colored tube representations. Color indicates the magnitude of RMSD shown in the right bar. In 
each PR, the left chain consists of P1-F99, and the right chain consists of P1’-F99’. Each model was fitted 
to PR(B:WT)NFV using the coordinates of main chain atoms N, C?, and C of PR. The superimposed gray 
tubes represent the average structure of PR(B:WT)NFV. Each structure is drawn by the PyMOL ver. 
0.99.rc6.87 
 
 
Figure 6.8. RMSD measured of the average structure of the individual residues from that of PR(B:WT)NFV. 
The right color bar is the magnitude of RMSD and corresponds to the bottom bar in Figure 6.7. Each model 
was fitted to PR(B:WT)NFV using the coordinates of main chain atoms N, C?, and C of PR. Black dots 
represent the locations of the active site residues of PR. 
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Figure 6.9. 3D plot of RMSD of NFV in the average structure of each model from that of PR(B:WT)NFV. 
NFV is shown in the colored stick representations. Color indicates the magnitude of RMSD shown in the 
right bar. Each model was fitted to PR(B:WT)NFV using the coordinates of main chain atoms N, C?, and C 
of PR. The superimposed gray sticks represent NFV in the average structure of PR(B:WT)NFV. Each 
structure is drawn by the PyMOL ver. 0.99.rc6.87 
 
Table 6.3. Volume and surface area of the binding cavity in each model. 
 WT M36I M36V D30N D30N/M36I D30N/M36V 
Volume (Å3) 375±43 345±36 365±43 403±53 419±53 375±47 
Surface area (Å2) 490±43 471±35 469±47 508±40 506±54 484±48 
 
We examined the effect of mutation at the 36th residue on volume of the active site (Table 
6.3). M36I reduces the volume of the active site, whereas both D30N and D30N/M36I increase it. M36V 
and D30N/M36V have almost no effect on the volume. 
Binding Energy Calculations. Binding energy between each PR and NFV is presented in Table 6.4. A 
single M36I or M36V mutation has almost no effect on the binding affinity with NFV, although the 
binding energy calculations have large standard deviations. In contrast, D30N and D30N/M36I mutations 
reduce the binding energies with NFV. Oppositely, D30N/M36V increases the affinity. Clemente et al. 
reported the 50% inhibitory concentration (IC50) values of PR(B:WT)NFV, PR(B:D30N)NFV, 
PR(B:M36I)NFV, and PR(B:D30N/M36I)NFV,
65 in which M36I was suggested to improve the binding 
affinity with NFV, and showed that D30N/M36I conferred resistance against NFV. Our results are 
compatible with those experimental results. 
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Table 6.4. Binding free energy of each model. 
 ?G int
ele  
(kcal/mol) 
?G int
vdW  
(kcal/mol) 
?G sol
  
(kcal/mol) 
?G b
 * 
(kcal/mol) 
??G b
   
(kcal/mol) 
IC50
 † 
(nM) 
WT -12.5±1.4 -71.8±3.8 15.1±1.4 -69.2±3.7 - 1.2±0.2 
M36I -11.8±1.2 -73.3±3.7 15.4±1.1 -69.7±3.5 -0.5 0.9±0.1 
M36V -13.2±1.5 -72.1±3.8 16.5±1.3 -68.8±3.6 0.4 ND ‡ 
D30N -6.9±1.2 -70.5±4.1 10.9±0.9 -66.5±3.9 2.7 6.8±0.9 
D30N/M36I -8.1±1.2 -66.8±3.6 9.8±1.1 -65.0±3.5 4.2 6.0±1.0 
D30N/M36V -10.8±1.2 -72.8±3.9 13.3±1.0 -70.3±4.0 -1.1 ND 
* -T?S 
  is not included. 
† Reference from the report by Clemente et al.65 
‡ ND denotes no data. 
 
We additionally analyzed the contribution of each residue to the binding of NFV (Figure 
6.10). In PR(B:M36I)NFV, PR(B:M36V)NFV, and PR(B:D30N/M36V)NFV, the respective residues except 
D25/D25’ have contributions similar to those in PR(B:WT)NFV. The contribution of D25/D25’ depends on 
their protonation states. In contrast, PR(B:D30N)NFV reduces the binding energy between the 30th residue 
and NFV. PR(B:D30N/M36I)NFV lowers the interaction between D29 and NFV. 
 
Figure 6.10. (a) Contribution of the individual residues to binding free energy. (b) Difference in 
contribution of the individual residues to the binding energy between each mutant and PR(B:WT)NFV. The 
energetic contributions of the residues are shown in red solid lines, and those of PR(B:WT)NFV in green 
lines. The bottom black lines indicate the locations of the active site residues (R8, L23-V32, I47-I50, 
P81-I84, R8’, L23’-V32’, I47’-I50’, P81’-I84’). 
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Discussion 
Here, we performed MD simulations of HIV-1 PRs in complex with NFV for the purpose of 
clarifying (1) the structural role of non-active site mutation M36I and (2) the relationship between D30N 
and M36I mutations. M36V was also examined in order to analyze the effect of the side-chain of the 36th 
residue. 
Non-subtype B HIV-1 is still pandemic in the world.1 Nevertheless, a standard protocol of 
chemotherapy for non-subtype B viruses has not yet been established,153 and little is known about the 
difference between susceptibilities of non-subtype B viruses and subtype B virus to clinically available 
drugs.27,46,97,144,145,154 M36I is the most frequently observed polymorphism among non-subtype B HIV-1 
PRs.50,149,150 Therefore, M36I is a key mutation to clarify the difference of efficacy of PIs among subtypes. 
Some studies have indicated that M36I is related to resistance against NFV and other FDA-approved PIs 
by complementing the effects of other resistant mutations.13,46,65 For example, M36I has been shown to 
contribute to an increase in the emergence rate of the NFV-resistant mutation N88S.46 It has also been 
reported that single M36I mutation does not confer resistance against the FDA-approved PIs.65 The 
structural role of M36I is, however, not clear because the 36th residue of PR is located at non-active site 
of HIV-1 PR. According to the results of the present simulations, single M36I mutation reduces the 
volume of the binding cavity of subtype B HIV-1 PR. Energetically, M36I PR slightly increases the 
binding affinity with NFV, compared with WT PR. This result is compatible with an experimental 
finding.65 Single M36V mutation also reduces the volume of the cavity, although the effect of M36Von 
the cavity volume is not as great as that of M36I.  
 
Figure 6.11. Contribution of the respective residues to the binding free energy with the 36th residues. 
Binding energy of each residue is presented by red solid lines, and those of PR(B:WT)NFV by green lines. 
Binding energies of the 35th and 37th residues are omitted, because they are adjacent to the 36th residue. 
Bottom black lines represent the locations of the active site residues of PR. 
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Figure 6.12. Interactions of the 36th residues with L33 and with V77. The average structure of 
PR(B:WT)NFV was superimposed onto that of PR(B:M36I)NFV using the coordinates of main chain atoms 
N, C?, and C in PR. The superimposed structure of PR(B:WT)NFV is shown in gray sticks and cartoons 
representation. The orange arrow indicates the locations of the 80’s loop, where a prominent change of 
conformation occurred by M36I. Each structure is drawn by the PyMOL ver. 0.99.rc6.87 
 
In order to reveal the mechanism how the non-active site mutation M36I regulates the volume 
of active site of PR, we additionally calculated the interaction energy between each residue of PR and the 
36th residue. The energy calculations suggest that the 36th residue mainly interacts with I15/I15’, 
Q18/Q18’, K20/K20’, L33/L33’, and V77/V77’ (Figure 6.11). Among these residues, L33/L33’ and 
V77/V77’ are located near active site residues (Figure 6.12). V77/V77’ is close to the 80’s loop, which 
consists of the residues from P79/P79’ to P81/P81’. L33/L33’ is in the vicinity of T31/T31’. Interestingly, 
mutations at L33 and V77 (L33F and V77I) are also related to the resistance against some PIs.13 These 
mutations would play a role similar to that of M36I. We speculate that the slight inward shifts of 
L33/L33’ and V77/V77’ due to the M36I mutation trigger the reduction in volume of the cavity of PR. In 
order to confirm this speculation, we further examined the shift of each residue and extracted the shift 
only toward the center of the active site (Figure 6.13 and 6.14). The results show that M36I causes a 
shrinkage of the active site around P79 and around T31’. The 31st residue T31/T31’ creates stable 
hydrogen bond networks with D29, T74, and N88 or with D29’, T74’, and N88’ (Table 6.5). Therefore, 
M36I also indirectly influences the conformations around D29/D29’. A28’, D29’, D30’, and T31’ in one 
monomer are all displaced inward. In contrast, A28 and D29 show outward positional shifts, while the 
residues around L33 in the other monomer move inward. It is notable that these residues rotate on D30. 
M36I hardly shrinks or expands the cavity at D30. However, D30 shifts toward the ?-helix region 
(R87–I93) in PR(B:M36I)NFV (Figure 6.15). Although this displacement is very slight (0.4 Å), the shift 
enlarges the distance from the main chain of D30 to the m-phenol group of NFV, and it also shortens the 
distance from the side-chain of D30 to NFV (Figure 6.5). Therefore, M36I changes the interaction 
 - 89 -
between D30 and NFV. D30 is an important residue for binding with NFV, as stated in the previous 
chapters. PR(B:M36I)NFV has a hydrogen bond with the m-phenol group of NFV only by the side-chain of 
D30, unlike PR(B:WT)NFV. PR(B:WT)NFV forms hydrogen bonds with the m-phenol group of NFV by 
either the main chain or the side-chain of D30. These results show that the non-active site mutation M36I 
influences the shape of the active site of PR by the following mechanism. M36I mutation shifts L33/L33’ 
and V77/V77’ inward. Subsequently, these shifts cause changes in conformation at the active site, 
especially around T31/T31’ and P79/P79’. 
 
 
Fig. 6.13. Positional shift of each residue measured from the center of the binding cavity in the average 
coordinate of WT PR. Negative values indicate contraction of distances measured from the center of the 
cavity, and positive values indicate elongation of the distances. Bottom black lines represent the locations 
of the active site residues. 
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Fig. 6.14. Structure of the binding pocket of each model, shown in the surface representation. (a) Definition 
of the label for each monomer. (b) Surface around the active site in each monomer. Color indicates the 
magnitude of positional shift of each residue measured from the center of the binding cavity in the average 
coordinate of WT PR, as gradated in the level of the bottom bar. Each model was fitted to PR(B:WT)NFV 
using the coordinates of main chain atoms N, C?, and C of PR. The superimposed meshes represent surface 
in the average structure of PR(B:WT)NFV. Blue lines represent atom geometry of NFV. Each structure is 
drawn by the PyMOL ver. 0.99.rc6.87 
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Table 6.5. Hydrogen bond networks around D29/D29’ and T31/T31’ in each PR. 
Donor Acceptor % * Donor Acceptor % 
WT D30N 
N N88 O D29 † 65.4 N N88 O D29 80.6 
N N88’ O D29’ 85.1 N N88’ O D29’ 63.5 
OG1 T31 OD1 N88 96.1 ND2 N30 O T31 98.1 
N T31 OD1 N88 86.7 ND2 N30 O T74 89.7 
O WAT220 O T31 71.6 N T31 ND2 N30 67.9 
N T31 O WAT220 65.7 ND2 N30 N T31 59.5 
OG1 T31’ OD1 N88’ 99.1 ND2 N30’ O T74’ 99.8 
N T31’ OD1 N88’ 81.9 ND2 N30’ N T31’ 56.4 
O WAT2551 O T31’ 55.4 N T31 OD1 N88 99.1 
O T31’ O WAT2551 53.1 OG1 T31 OD1 N88 92.9 
O WAT220 O T74 72.7 N T31’ OD1 N88’ 99.8 
N T74 O WAT5693 68.9 OG1 T31’ OD1 N88’ 91.7 
ND2 N88 O T74 64.0 ND2 N88 O T74 99.6 
ND2 N88’ O T74’ 88.8 ND2 N88’ O T74’ 99.1 
O WAT2551 O T74’ 55.5      
ND2 N88 O WAT220 68.8      
O N88 O WAT5693 55.4      
ND2 N88’ O WAT2551 50.2      
M36I D30N/M36I 
N N88 O D29 59.8 N N88 O D29 98.8 
N N88 O D29’ 83.3 N N88’ O D29’ 86.0 
OG1 T31 OD1 N88 97.1 ND2 N30 O WAT222 70.7 
N T31 OD1 N88 75.7 OG1 T31 OD1 N88 99.6 
N T31 O WAT3754 58.6 N L76 O T31 99.4 
O WAT3754 O T31 59.7 N G86 OG1 T31 96.5 
N T31’ OD1 N88’ 91.8 N T31 O WAT222 79.6 
OG1 T31’ OD1 N88’ 99.0 O WAT222 O T31 71.7 
ND2 N88 O T74 86.5 N T31’ OD1 N88’ 86.2 
O WAT3754 O T74 60.5 OG1 T31’ OD1 N88’ 84.8 
ND2 N88 O T74’ 92.0 N L76’ O T31’ 88.7 
ND2 N88 O WAT3754 51.9 N G86’ OG1 T31’ 81.2 
     N T31’ O WAT207 70.7 
     O WAT207 O T31’ 65.2 
     O WAT222 O T74 85.9 
     O WAT297 O T74’ 82.0 
     ND2 N88 O T74 99.6 
     ND2 N88’ O T74’ 99.1 
M36V D30N/M36V 
N N88 O D29 71.9 N N88 O D29 80.5 
N N88 O D29’ 85.7 N N88 O D29’ 79.2 
OG1 T31 OD1 N88 99.0 ND2 N30 O WAT222 62.3 
N T31 OD1 N88 87.2 OG1 T31 OD1 N88 95.2 
OG1 T31’ OD1 N88’ 99.3 N T31 OD1 N88 96.5 
N T31’ OD1 N88’ 86.8 OG1 T31’ OD1 N88’ 96.6 
N T31’ O WAT927 56.0 N T31’ OD1 N88’ 83.0 
O WAT927 O T31’ 57.5 N T31’ O WAT207 56.6 
ND2 N88 O T74 93.5 ND2 N88 O T74 94.7 
ND2 N88’ O T74’ 83.2 O WAT222 O T74 52.3 
ND2 N88’ O WAT927 54.1 ND2 N88’ O T74’ 85.5 
     O WAT207 O T74’ 58.7 
     ND2 N88’ O WAT207 50.1 
* Occupancy of hydrogen bonds during the 2.0-3.0 ns MD simulation. 
† D29/D29’, D30/D30’, N30/N30’, and T31/T31’ are highlighted in bold face. 
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Figure 6.15. Interactions between D30 and NFV. Colored sticks and cartoons represent an average structure 
of PR(B:M36I)NFV, and white sticks and cartoons show that of PR(B:WT)NFV. Each structure is drawn by 
the PyMOL ver. 0.99.rc6.87 
 
It is informative to investigate the relationship between D30N and M36I. Non-subtype B 
HIV-1 PRs commonly carry M36I as a polymorphism.50,149,150 In contrast, D30N rarely appears in 
non-subtype B HIV-1 PRs.26,27,50 This rare emergence of D30N in non-subtype B PRs has been assumed 
to be due to the low viral replication ability of D30N mutants in non-subtype B viruses,27,155 because 
L89M, which is a polymorphism of some non-subtype B PRs, and D30N decrease the replication 
ability.27,155 On the other hand, our simulations provide a novel insight into the relationship between 
D30N and M36I. It should be noted that PR(B:D30N/M36I)NFV forms a hydrogen bond between the main 
chain of N30 and NFV (Figure 6.5), which is not seen in PR(B:D30N)NFV. Although 
PR(B:D30N/M36I)NFV confers resistance against NFV,
65 the resistance is caused by the distortion at D29, 
not by the loss of the hydrogen bond as PR(B:D30N)NFV. In the previous chapter, we examined the 
structural feature of CRF01_AE D30N PR with NFV. It is known that CRF01_AE HIV-1 PR carries 
M36I as a polymorphism and does not acquired D30N.46 CRF01_AE D30N PR also creates direct or 
one-water-molecule-mediated hydrogen bonds between NFV and the 30th residue and has binding 
affinity with NFV similar to CRF01_AE reference PR. These results suggest that M36I enforces the 
interaction between N30 and NFV in D30N mutant PR. Therefore, NFV will maintain its efficacy against 
D30N mutant PR in non-subtype B viruses, which causes the rare emergence of D30N in non-subtype B 
viruses. 
This chapter shows the structural role of non-active site mutation M36I of HIV-1 PR, which 
is common polymorphism in non-subtype B HIV-1. M36I induces slight but important changes of active 
site of PR. The change influences the PR-NFV binding. Our finding will be useful information to develop 
PIs which target non-subtype B HIV-1 PR. 
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Chapter 7 
Prediction of Effectiveness of PIs 
-Application of Computational Simulation- 
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Introduction 
 In the previous chapters, we show the structural roles of several drug-resistant mutations and 
polymorphisms in HIV-1 protease (HIV-1 PR) through computational simulations. In these chapters, we 
also estimate the binding energy between PR and its ligand. The binding energy calculations provide 
compatible results with experimental or clinical observations. Hence, it can be expected that the 
simulation method used in this study will also be applicable to the prediction of resistance or the selection 
of appropriate drugs to each patient. To confirm the hypothesis, we attempt to predict PI-resistance of two 
clinically isolated viruses, which have unusual combination of mutations. 
In recent years, some computational prediction methods of drug resistance have been 
proposed.156,157 The prediction methods are divided into two classes: sequence-based methods and 
structure-based methods.157 Sequence-based methods predict resistance by using rules or classifiers 
derived from statistical analyses of the sequences of resistant and non-resistant samples. In contrast, 
structure-based methods predict resistance by estimating the binding affinity between a receptor and a 
ligand on the basis of the tertiary structure of their complex. The structure is determined or predicted by 
X-ray crystallography, NMR, or computational simulations. The method used in the previous chapters is 
also classified into the structure-based methods. 
In the present clinical scene, only the sequence-based methods are applied because of their 
convenience. We can easily and quickly predict resistance by clinical isolates with the methods. However, 
when unusual or unknown combination of mutations is detected in a clinical isolate, it is difficult to 
accurately predict the resistance by the isolate with sequence-based methods. It is because the methods 
depend on rules derived from known data. On the other hand, structure-based methods do not depend on 
the rules. Therefore, it can be considered that structure-based methods are more applicable to the 
prediction of resistance by isolate with unusual sequence, although structure-based methods need much 
time for the prediction. We expect that structure-based methods will also be used in clinical scene in the 
near future, with the progress of performance of computer hardware. To the best of our knowledge, it is 
the first report to confirm that structure-based methods are able to predict resistance of clinically isolated 
HIV-1. 
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Materials and Methods. 
Clinical Isolates. The sequence and clinical information of two clinically isolated viruses are provided 
from Dr. Yokomaku at National Hospital Organization Nagoya Medical Center, Japan. From a patient, an 
isolate was found at 2006/03/20, and the other one at 2006/04/21. The former isolate confers resistance 
against SQV, NFV, and LPV/r. PR of the isolate has 13 mutations: L10I, I15V, N37D, M46I, I54V, L63P, 
A71V, I72L, G73S, V77I, V82T, I85V, L90M, and I93L. The isolate also causes high level of resistance 
against nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). However, it is surprising that HAART including fosamprenavir 
(FPV),81 which is the pro-drug of amprenavir (APV),  is sensitive to the isolate. In contrast, the later 
isolate also acquires resistance against FPV, although PR in the later isolate has two additional mutations: 
G16A and V32I. 
Molecular Dynamics (MD) Simulations. We perform minimizations and MD simulations in the same 
manner as that described in the chapter 4. We also determined the restrained electrostatic potential 
(RESP)111 charges for APV as described in the chapter 4. We perform simulations of three proteases in 
complex with APV: the wild-type (WT) PR of subtype B HIV-1, PRs in the isolates at 2007/03/20 and at 
2006/04/21 (labeled PR(B:WT)APV, PR(060320)APV, and PR(060421)APV, respectively) (Figure 7.1). We 
use HXB2 as the WT sequence. Each initial structure for PR in complex with APV is modeled from the 
atom coordinates of an X-ray crystal structure (PDB code: 1HPV) .92 In the present calculations, the MD 
simulations showed no large fluctuations after about 2.5 ns equilibrating calculation (Figure 7.2). Hence, 
atom coordinates are collected at an interval of 1.0 ps for the 2.5-3.0 ns to analyze the structure in detail.  
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Figure 7.1. (a) X-ray crystal structure of HIV-1 PR in complex with APV.92 The PR has two identical 
polypeptide chains, each of which consists of 99 residues P1-F99 and P1’-F99’. Locations of the mutated 
residues in PR(060421)APV are shown in sphere representations. Each structure is drawn by PyMOL ver. 
0.99.rc6.87 (b) Hydrogen bond network between PR and APV in the crystal structure.92 (c) Chemical 
structure of APV. (d) The amino acid sequence of the subtype B wild-type (WT) HIV-1 PR (HXB2) and 
that of two clinical isolates. 
 
 
Figure 7.2. RMSD plots during the 3.0 ns MD simulations about each PR. RMSD were calculated from 
coordinates of main chain atoms N, C?, C. Red and green lines represents RMSD values calculated from 
all residues and active site residues, respectively. The residues at codon 8, 23-32, 47-50, 81-84 were 
selected as the active site residues. ASP and ASH denote un-protonated and protonated aspartic acids. 
 
Next, the protonation states of the catalytic aspartates D25 and D25’ are determined as that 
described in the chapter 4. PR(B:WT)APV is found to prefer the combination of protonated D25 and 
un-protonated D25’. The other two clinically isolated PRs – PR(060320)APV and PR(060421)APV – prefers 
the combination of un-protonated D25 and protonated D25’ (Table 7.1). 
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Table 7.1. Total energy of each model of PR with APV. 
 B:WT 060320 060421 
ASP25/ASH25’* 904.8±43.0 860.0±48.2 871.6±42.7 
ASH25/ASP25’ 877.9±43.8†,‡ 880.0±42.5 887.6±43.6 
Energy is presented in units of kcal/mol. 
* Each ASP and ASH denotes un-protonated and protonated aspartates. 
† Bold representation shows the energetically lower model between two complexes. The energetically 
lower model was analyzed in this study. 
‡ See also Table 4.1. 
 
Binding Free Energy Calculation. The binding free energy in solution is calculated with the MM_PBSA 
method in the same manner as that described in the chapter 4. 
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Results 
Validation of the Computational Method for Prediction of Resistance. Before we predict resistance of 
the clinical isolates, we confirm if the computational results in the previous chapters have correlation with 
experimental data. It is known that resistant level has a relationship with the difference of binding 
energies between a mutant and the WT models ( ??G b
 ) as follow.156 
 ??G b
 
= RT ? ln(resistant level) ,   
  R 
 : the gas constant, T 
 : absolute temperature 
The resistant level is generally estimated from inhibitory concentrations (IC50 or IC90) or inhibitory 
constants (Ki) of a mutant and the WT virus. The results show that the calculated binding energies have 
high correlation with experimental data (r = 0.93, Figure 7.3). 
 
Figure 7.3. Correlation between the binding energies calculated in the previous chapters and 
experimentally determined resistant level. Red line represents the approximated line.  
 
Prediction of Drug Resistance against APV by Two Clinically Isolated HIV-1. We predicted drug 
resistance or susceptibility of two isolates to APV by the structure-based computational simulations. First, 
we calculated stable structure of the complex of each PR with APV by MD simulations. Next, we 
estimated the binding energy between each PR and APV using the MM_PBSA method. Then, resistance 
toward APV of each isolates was evaluated by using the binding energy relative to that of PR(B:WT)APV 
( ??G b
 ).16 If ??G b
  is a positive value, the PR indicates resistance to the inhibitor. On the other hand, if 
??G b
  is a negative value, it means susceptibility. The computational results expected that the PR at 
06/03/20 showed susceptibility to APV. In contrast, the prediction results indicated that the PR at 
06/04/21 conferred high resistance against APV. These results were compatible with the clinical 
observations. 
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Table 7.2. Binding free energy of each model with APV 
 ?G int
ele  ?G int
vdW  ?G sol
  ?G b
 * ??G b
 † Resistant 
level‡ 
B:WT -19.3±2.8 -62.7±3.4 10.4±1.2 -71.2±3.0 - - 
060320 -23.1±3.2 -61.7±3.4 10.5±1.7 -74.5±3.5 -3.3 0.3 
060421 -9.7±1.4 -51.7±3.5 3.5±0.3 -61.6±4.2 +9.6 91.0 
Energy is presented in units of kcal/mol. 
* -T?S is not included. 
† Difference of binding energy compared with that of PR(B:WT)APV. 
‡ Resistant level estimated from the calculated binding energy with the approximate line in Figure 7.3. 
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 Discussion. 
 In this chapter, we report the structure-based prediction methods are applicable to the 
prediction of effectiveness of anti-HIV-1 drugs against multi-drug-resistant HIV-1. 
 We predicted susceptibility or resistance against APV by clinically isolated two 
multi-drug-resistant HIV-1. In PR of an isolate, 13 mutations appeared, and some of them are associated 
with drug resistance against PIs. These mutations caused resistance against NFV, SQV, and LPV/r. The 
isolate also conferred high level of resistance against NRTIs and NNRTIs. However, it is surprising that 
the isolate showed susceptibility to a regimen of HARRT including FPV, which is the pro-drug of APV. 
In contrast, the other isolate conferred resistance against the same HARRT, although only two additional 
mutations G16A and V32I appeared in PR of the later isolate. To our knowledge, the combination of 
mutations in each PR is unusual. It should be noticed that the emergence of V32I confers resistance 
against APV, despite no appearance of I47V. It has been considered that the combination of V32I and 
I47V confers against APV, but single V32I mutation hardly influences the binding of APV.166 We 
predicted resistance against APV of these two peculiar isolates by a structure-based method. Our 
prediction proposed that the former isolate was susceptible to APV. In contrast, the prediction suggested 
that the later isolate was resistance against APV. The results are compatible with clinical data. By the way, 
the simulation indicated that the emergence of two additional mutations G16A and V32I increased the 
volume of the APV-binding cavity in PR(060421)APV , which is caused by the decrease of interactions 
between I50/I50’ and APV (Table 7.2 and Figure 7.4, 7.5). Therefore, the later isolate reduces the binding 
affinity of APV and confers high level of resistance against APV. We succeeded in the prediction of 
resistance of the clinically isolated multi-drug-resistant HIV-1 by the structure-based methods. This 
technique is further applicable to the decision of an appropriate drug to respective patients. 
 
Tabel 7.2. The volume of the binding cavity of PR and the distances between C? of D25 and C? of I50 
and between C? of D25’ and C? of I50’. 
  B:WT 060320 060421 
Cavity volume (Å3)  325±32 332±50 601±101 
Distance (Å)  C? of I50 - C? of D25 13.6±0.4 12.6±0.3 15.6±0.4 
 C? of I50’ - C? of D25’ 12.5±0.3 12.6±0.3 14.4±0.4 
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Figure 7.4. Distance between APV and I50/I50’ of PR. Red solid line correspond to the distance of O1 
atom in APV with N in I50 or I50’. Green and blue solid lines correspond to the distance of O2 and O3 
with N in I50/I50’ respectively. 
 
 
Figure 7.5. Interactions of the 32nd residue of PR(B:WT)APV. The PR was shown in cartoon 
representation and the 32nd, 47th, 76th, 50th, and 84th residues were shown in ball and stick 
representation. The 32nd residues are also highlighted with mesh representation. APV was shown in stick 
representation. 
 
In general, prediction of resistance of clinical isolates is performed with sequence-based 
methods. It is because sequence-based prediction methods need only sequence data of isolates, and the 
predictions are so fast. However, since the methods depend on rules or classifiers derived from statistical 
analyses of the sequences of resistant and non-resistant samples, it is hard to predict resistance of strange 
isolates by sequence-based methods. In fact, a sequence-based method by the Stanford HIVdb 
program55,158 did not predict susceptibility of APV toward the former isolate. When we performed 
sequence-based prediction of these two isolates by the HIVdb program, the results showed that the former 
isolate conferred intermediate level of resistance and the later one confers high level of resistant against 
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APV. It should be noticed that, even if a lot of mutations emerge in a clinical isolate, the isolate do not 
always confer resistance against all of anti-HIV drugs. 
 In this chapter, we show that our simulation methods are applicable to the prediction of 
drug-resistance of clinical isolates. To the best of our knowledge, it is the first report to confirm that 
structure-based method is able to predict resistance of clinically isolated HIV. We expect that 
structure-based method will also be used in clinical scene in the near future, with the progress of 
performance of computer hardware and accuracy of simulations. 
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Chapter 7 
Summary 
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This study clarifies the resistant mechanisms against PIs not only due to active site mutations 
D30N in HIV-1 PR, but also non-active site mutations L90M and N88S. The emergence of D30N in 
subtype B HIV-1 PR confers resistance because of the loss of hydrogen bonds between NFV and the 30th 
residue. L90M changes conformation at active site of PR and reduces the binding affinities of some PIs, 
although the 90th residue is located at the non-active site. N88S reduces the interactions between NFV 
and the 30th residue. We also investigate structural role of polymorphisms in non-subtype B viruses. The 
polymorphisms in CRF01_AE HIV-1, especially M36I, influence the emergence rates of D30N and N88S 
in HIV-1 PR, although the polymorphisms occur at non-active site of PR. Some groups also have 
reported that non-active site mutations and polymorphisms influence the binding affinity of some 
inhibitors, the emergence rate of mutations, and the catalytic activity of HIV-1PR. 65,72,74,97,137,146-148 
However, there have been few studies on the influence of non-active site mutations from a structural 
viewpoint. There have also been few studies on the differences between HIV-1 subtypes. Clarification of 
the roles of non-active site mutations and polymorphisms will enable us to design potent drugs to treat 
HIV/AIDS, since the currently available PIs were developed and tested only against subtype B PRs. 
Furthermore, this study also indicates that the simulation techniques will be applicable to 
predict resistance against PIs of clinically isolated HIV-1. The techniques will also be useful for selecting 
more appropriate drugs for patients. 
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Appendix 
Molecular Dynamics (MD) 
 Molecular dynamics (MD) is one of the techniques of computer simulations. In MD 
simulation, atoms and molecules are allowed to interact for a period of time under known laws of physics. 
Therefore, MD gives a view of the motion of the atoms. 
 For a system of N atoms, the following pair of first order differential equations may be 
written in Newton's notation as 
F X( ) = ??U(X)=M
d
dt
V(t) V(t) =
d
dt
X(t) . 
The potential energy function U of the system is a function of the atom coordinates. The first equation 
comes from Newton's laws; the force F acting on each atom in the system can be calculated as the 
negative gradient of U(X). For every time step in MD, each atom's position X and velocity V may be 
integrated with a symplectic method such as Verlet. 
In the AMBER force field, the potential energy U is written in the following equation. 
U = Kr (r ? req )
2
bonds
?  bond 
+ K? (? ?? eq )2
angles
?  angle 
+
Vn
2
(1+ cos[n? ?? ])
torsions
?  torsion 
+
Aij
R ij
12
?
Bij
R ij
6
i< j
atoms
?  van der Waals 
+
q iq j
?Rij
i< j
atoms
?  electrostatic 
The function contains the bonded energy term (bond stretching, angle bending, and torsional rotation) and 
the non-bonded energy term (van der Waals and electrostatic interactions). 
MD represents an interface between laboratory experiments and theory, and we can 
understand it as a "virtual experiment".
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MM_PBSA/GBSA 
The MM_PBSA/GBSA approach represents the post-processing method to evaluate “free 
energies of binding” or to calculate “absolute free energies” of molecules in solution. The sets of 
structures are usually collected with molecular dynamics (MD) or Monte Carlo methods. The 
MM_PBSA/GBSA method combines the molecular mechanical (MM) energies with the continuum 
solvent approaches.  
The absolute free energy in solution G is calculated by the following equation,  
 G = G MM +G sol
 ?TS ,  
 GMM =G int +G int
ele
+G int
vdW ,  
 G sol =G sol
ele
+G sol
nonpol, 
where G MM
 , and G sol
  are the MM energy and the solvation energy, and -TS is the contribution of 
conformational entropy to the binding. G MM
 represents the internal energy (bond, angle, torsion) ( G int
 ) 
and the van der Waals and the electrostatic interaction energies (G int
vdW  and G int
ele ). The electrostatic 
contribution to the solvation free energy (G sol
ele ) is calculated with a numerical solver for the 
Poisson-Boltzmann (PB) method, or by generalized Born (GB) methods. The non-polar contribution to 
the solvation free energy (G sol
nonpol ) has been determined with solvent-accessible-surface-area-dependent 
terms.  
 The binding free energy between a receptor and a ligand ( ?G b
 ) is represented by the 
following equation,  
 ?G b
 
= G com
 ? (G rec
 
+G lig
 ) , 
where G com
 , G rec
 , and G lig
  are the absolute free energies of complex, receptor, and ligand, 
respectively. Hence, ?G b
 is also written as  
 
?G b = ?G MM +?G sol ?T?S
= (?G intele +?G intvdW ) + (?G solele +?G sol
nonpol )?T?S
 
 
 
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
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??????????????????? ????? ?????????????????
???????????????????????????
?
??????????????(AIDS)?????????? Human Immunodeficiency Virus Type 1 
(HIV-1)??????20 ?????????????? HIV-1 ?????????????????
?????? 11????????????????? 9?????????????HIV/AIDS??
?????????????? HIV-1 ?? AIDS???????????????????????
????????? HIV-1 ?????? AIDS ????????HIV/AIDS ???????????
?????????????HIV-1??????????????????? HIV-1???????
????????????HIV-1 ??????????????????????????????
??????????HIV/AIDS????????????????? 
 HIV-1 ???????????????
???????????????????????
???????????????????????
?????????????HIV-1 ??????
(HIV-1 PR?? 1)??????????(Active Site)
???????????????(Non-active Site)?
???????????????????????
??????????HIV-1???????????
????????????(NFV)????????
???????????????????????
???HIV-1 PR????????????????
???????????????????????
???? MM_PBSA/GBSA?????? 
 
????????? 
1. Subtype B HIV-1 PR???? Active Site?? D30N????? 1,3 
 HIV-1 ? Sub-type ???
????????????? Subtype 
B HIV-1 ??????????NFV
?????????? Subtype B 
HIV-1????????? HIV-1 PR
? 30 ?????????????
????????? (D30N)???
???D30N??? NFV?????
?????????????????
HIV-1 PR? 30 ?????????
????????? Active Site?? 
????????????????wild-type (WT) HIV-1 PR???????? D30-NFV???????
D30N HIV-1 PR??????NFV??????????????????????? (? 2)?Subtype 
B HIV-1 ??PR? D30N???????NFV-30??????????????NFV???????
????????????? 
 
? 1. HIV-1 PR-????????????
HIV-1 PR ? 99 ????????????
???????? 
 
? 2. Subtype B WT HIV-1 PR-NFV ???????
D30-NFV?????? D30N HIV-1 PR-NFV?????
?? N30-NFV???????????????????? 
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2. Subtype B HIV-1 PR???? Non-active Site?? L90M????? 2 
 NFV??????????
Subtype B HIV-1 ?????????
?????????????? L90M
??????L90M????NFV ??
???????? (SQV) ?????
?????????????????
?????????????????
HIV-1 PR ? 90 ?????Non-active 
Site ???????????????
????????????????? 
??L90M????????????????????????????????Non-active Site??
? L90M?????????? HIV-1 PR? Active Site????????????????????
?????????L90M?????90??????????? Active Site??? D25/D25’????
???????D25/D25’?????????????? Active Site ??? I84/I84’????????
?????Active Site? Flap????????????? (? 3)????????????????
?????????????????????????L90M ?????????????????
????????????????????? 
 
3. CRF01_AE HIV-1 PR???? Non-active Site?? N88S????? 3 
 CRF01_AE HIV-1 ????
NFV ?????????????
Subtype HIV-1 ????????N88S
???????????????
Subtype B HIV-1??????N88S?
? ? ? ? ? ? ? ? ? ? ? ? ?
CRF01_AE HIV-1?????????
?????????????????
??? HIV-1 ????N88S ???
L90M ?????? HIV-1 PR ?
Non-active Site???????????
????????????CRF01_AE 
Reference HIV-1 PR????????
D30??-NFV????????N88S 
HIV-1 PR?? D30??-S88???????????????????????????????N88S 
PR?? NFV????????????????????????? 
????CRF01_AE HIV-1PR????????? (Polymorphism) ??N88S??????
???????????????CRF01_AE HIV-1PR ?????????? M36I ??? N88S??
?NFV???????????????????Subtype B N88S HIV-1 PR??Subtype B WT HIV-1 PR
???? NFV?????????? 
 
4. CRF01_AE HIV-1 PR?????????? D30N?????? 3,4 
 NFV?????????? Subtype B HIV-1?????D30N?????????????
 
? 3. Subtype B WT HIV-1 PR-NFV???? L90M HIV-1 
PR-NFV???????????L90M HIV-1 PR????
???????????????? 
 
? 4. CRF01_AE Reference HIV-1 PR-NFV???? N88S 
HIV-1 PR-NFV ?????????????? D30 ??
??????Reference PR???? D30??? NFV??
????????????N88S PR???? D30???
???? S88 ???????????????????
??? 
  - 109 - 
?????????CRF01_AE HIV-1?????????D30N???????????N88S???
??CRF01_AE HIV-1PR?????????? D30N?????????????????????
?????????CRF01_AE D30N HIV-1PR???Subtype B D30N HIV-1PR?????????
N30-NFV??????????????????CRF01_AE Reference HIV-1PR?????????
???CRF01_AE HIV-1PR???????????CRF01_AE HIV-1???? N88S???????
??????D30N ??????????????????????????????????M36I
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?? A??????????? B??????????????????????? 
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??N88S ????????????????????????????????????? HIV-1
???????? HIV-1??????????????????????????????????
????????????HIV/AIDS???????????????????????? 
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